EP0920253A1 - Il-8 receptor antagonists - Google Patents

Il-8 receptor antagonists

Info

Publication number
EP0920253A1
EP0920253A1 EP97939515A EP97939515A EP0920253A1 EP 0920253 A1 EP0920253 A1 EP 0920253A1 EP 97939515 A EP97939515 A EP 97939515A EP 97939515 A EP97939515 A EP 97939515A EP 0920253 A1 EP0920253 A1 EP 0920253A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
alkyl
4alkyl
heterocychc
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97939515A
Other languages
German (de)
French (fr)
Other versions
EP0920253A4 (en
Inventor
Deborah Lynn Bryan
John Gerald Gleason
Katherine L. Widdowson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0920253A1 publication Critical patent/EP0920253A1/en
Publication of EP0920253A4 publication Critical patent/EP0920253A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton

Definitions

  • This invention relates to novel guanidine substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 mediated diseases
  • Interleuk ⁇ n-8 Interleuk ⁇ n-8
  • NAP-1 neutrophil attractant/activation protein- 1
  • MDNCF monocyte derived neutrophil chemotactic factor
  • NAF neutrophil activating factor
  • Interleuk ⁇ n-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-l ⁇ , IL-l ⁇ or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP.
  • GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 and NAP-2 also belong to the chemokine a family Like IL-8 these chemokmes have also been referred to by different names For instance Gro ⁇ , GRO ⁇ , and GRO ⁇ have been referred to as MGSA ⁇ , ⁇ and ⁇ respectively (Melanoma Growth Stimulating Activity), see Richmond et ai, J Cell Physiology 129, 375 (1986) and Chang et al, J Immunol 148, 451 (1992) All of the chemokmes of the a-family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor.
  • IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 stimulate a number of functions in vitro They have all been shown to have chemoattractant properties for neutrophils, while IL-8 and GROa have demonstrated T-lymphocytes, and basophiles chemotactic activity
  • IL-8 can induce histamine release from basophils from both normal and atopic individuals
  • GRO- ⁇ and IL-8 can in addition, induce lysozomal enzyme release and respiratory burst from neutrophils
  • IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis This may contribute to increased adhesion of the neutrophils to vascular endothelial cells
  • Many known diseases are characterized by massive neutrophil infiltration As IL-8.
  • IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-hnked family, in particular by binding to IL-8 receptors, most notably the B-receptor Thomas et al , J Biol Chem 266. 14839 ( 1991 ). and Holmes et al . Science 253. 1278 ( 1991 )
  • the development of non-peptide small molecule antagonists for members of this receptor family has precedent For a review see R Freidinger in Progress in Drug Research.
  • IL-8Ra which binds only IL-8 with high affinity
  • IL-8Rb which has high affinity for IL-8 as well as for GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2
  • IL-8Ra which binds only IL-8 with high affinity
  • IL-8Rb which has high affinity for IL-8 as well as for GRO ⁇ , GRO ⁇ , GRO ⁇ and NAP-2
  • This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
  • the chemokine is IL-8.
  • This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal m need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
  • R is any functional moiety having an lomzable hydrogen and a pKa of 10 or less
  • R is independently selected from hydrogen; halogen; nitro; cyano: halosub.stituted Ci- io alkyl; C ⁇ _ ⁇ o alkyl; C2-10 alkenyl; C i- io alkoxy; halosubstituted C i- io alkoxy; azide; (CR R 8 )q S(O)tR4; hydroxy; hydroxy C j-4alkyl; aryl; aryl C j-4 alkyl: aryloxy; aryl C
  • R6 and R7 are independently hydrogen or a C j -4 alkyl group, or R and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, R is independently selected from hydrogen or C j-4 alkyl,
  • R l 1 is hydrogen, C 1-4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi -4aikyl, optionally substituted heterocychc, or optionally substituted heterocychcC ⁇ -4alkyl
  • R l2 is hydrogen, C j - io alkyl, optionally substituted aryl or optionally substituted arylalkyl
  • R 13 and R 14 are independently hydrogen or C ] -4 alkyl
  • R l5 and R j ⁇ are independently hydrogen, optionally substituted C ) -4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi -4alkyl, optionally substituted heterocychc, optionally substituted heterocychcC j -4alkyl, 01 R 55 and R 16 may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur, R 17 is C 1 -4 alkyl, NR ⁇ 5R 1 (., OR ⁇ ⁇ , optionally substituted aryl, optionally substituted aryl C ] -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocychc.
  • R l 8 is optionally substituted C i-4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i -4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC i -4alkyl,
  • R l9 is C [ -4alkyI, aryl, arylalkyl, heteroaryl, heteroarylC] _4alkyl, heterocychc, or heterocychcC i-4alkyl, wherein the all of these moieties may be optionally substituted, is NR6R7, alkyl, arylC j_4 alkyl, arylC 2-4 alkenyl. heteroaryl, hetroaryl-Cj _4alkyl, heteroarylC2-4 alkenyl. heterocychc, heterocychcC 1.4 alkyl, wherein the alkyl. aryl, arylalkyl.
  • R20 is an optionally substituted C5_g cycloalkyl, optionally substituted C ⁇ . ⁇ Q alkyl, optionally substituted C2- 10 alkenyl, or optionally substituted C2-10
  • the E' containing ring is optionally selected from
  • the compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokmes which bind to the IL-8 a and b receptors
  • Chemokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section
  • (*) may optionally be present If if it is not present the ring is a phenyl moiety which is substituted by the R ⁇ terms as shown
  • the E' ring may be substituted by
  • R is suitably any functional moiety which provides an lonizable hydrogen having a pKa of 10 or less, preferably from about 3 to 9, more preferably from about 3 to 7
  • Such functional groups include, but are not limited to, hydroxy, carboxyhc
  • sulfonamides 10 acid, thiol, SR2, OR2, NH-C(O)R a , C(O)NR6'R7 ⁇ a substituted sulfonamides of the formula- NHS(O)2Rb, S(O)2NHR c> NHC(X 2 )NHRb, or a tetrazolyl; wherein X 2 is oxygen or sulfur, preferably oxygen
  • the functional group is other than a sulfonic acid, either directly or as a substituent group on the aryl, heteroaryl, or heterocychc moiety ring, such as in SR2 or OR2 More preferably R is OH. SH, or i s NHS ( O)2Rb
  • R2 is a substituted aryl, heteroaryl, or heterocychc moiety which ring has the functional moiety providing the lonizable hydrogen having a pKa of 10 or less
  • R6' and R7' are hydrogen, Ci-4 alkyl, aryl, arylC i -4alkyl, 0 arylC2-4alkenyl, heteroaryl, heteroarylC i-4alkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychc Cj-4alkyl, heterocychc C2-4alkenyl moiety , all of which may be optionally substituted one to three times independently by halogen; nitro, halosubstituted C1-4 alkyl, such as CF3, C 1.4 alkyl, such as methyl, C j-4 alkoxy, such as methoxy.
  • R6 and R7 are independently hydrogen or a C i -4 alkyl group, or R and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur This hetero ⁇ ng may be 0 optionally substituted as defined herein
  • R a is an aryl, arylC i-4alkyl, heteroaryl, heteroarylC ] -4alkyl, heterocychc, or a heterocychc C
  • _4alkyl moiety all of which may be optionally substituted, as defined herein below
  • Rb is a NR6R7 , alkyl, aryl, arylC
  • R9 is hydrogen or a C 1 -4 alkyl, preferably hydrogen
  • R a is preferably an alkyl group, such as methyl
  • R c is hydrogen, alkyl, aryl, arylC ⁇ _4alkyl, arylCj-4alkenyl, heteroaryl, heteroarylCi-4alkyl, heteroarylC i-4alkenyl, heterocychc, heterocychc C i-4alkyl, or heterocychc C ) -4alkenyl moiety, all of which may be optionally substituted one to three times independently by halogen, nitro, halosubstituted C j-4 alkyl, C1.4 alkyl, C i -4 alkoxy.
  • NR9C(0)R a C(O)NR6R7, S(O)3H. or C(O)OCi-4 alkyl
  • R a is preferably an alkyl group, such as methyl
  • R c is hydrogen, alkyl,
  • R is an OR2 or SR2 moiety it is recognized by one of skill in the art that the aryl ring must, therefore, contain the required lonizable hydrogen
  • the aryl ring may also be additionally substituted, independently, by one to three groups, which groups may also contain an additional lonizable group, and which include but are not limited to, halogen, nitro, halosubstituted C 1 -4 alkyl, C 1.4 alkyl, C 1.4 alkoxy, hydroxy, SH, C(O)NR6R7, NH-C(O)R a , NHS(O)2Rb- S(O)2NR6R7, C(O)OR 8) or a tetrazolyl ring
  • R] is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted C j- io alkyl, such as CF3, C i-io alkyl, such as methyl, ethyl, isopropyl, or n-propyl; C2-10 alkenyl.
  • q is 0, or an integer having a value of 1 to 10
  • s is preferably 1
  • R[ forms an additional saturated or unsaturated ring it is preferably 6 membered ring resulting in a naphthylene ring system
  • R4 and R5 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C ]-4alkyl, heterocychc, heterocychcC 1-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S.
  • Rg is suitably independently selected from hydrogen or C ( -4 alkyl Rio i suitably C ⁇ . ⁇ () alkyl C(0)2Rg, such as CH2C(0)2H or
  • Rl 1 is suitably hydrogen, Ci-4 alkyl, aryl, aryl C [ -4 alkyl. heteroaryl, heteroaryl C
  • R l2 is suitably hydrogen, C l- 10 alkyl, optionally substituted aryl or optionally substituted arylalkyl
  • Rj9 is C j-4alkyl, aryl, arylalkyl, heteroaryl, heteroarylCi-4alkyl, heterocychc, or heterocychcC i-4alkyl, wherein the all of these moieties may be optionally substituted.
  • Ri is halogen, cyano, nitro, CF3, C(O)NR4R5, alkenyl C(O)NR4R5, C(O) R4R 10. alkenyl C(0)OR ]2.
  • R4 and R5 are both hydrogen or one is phenyl
  • a preferred ring substitution for R i is in the 4-pos ⁇ t ⁇ on of the phenyl ring.
  • R is OH, SH or NSO2Rb than Rj is preferably mono-substituted in the 3-pos ⁇ t ⁇ on, the 4- position or is di substituted in the 3,4- position
  • the substituent group is suitably an electron withdrawing moiety
  • R is OH, SH or NSO2Rb. than Rl is nitro, halogen, cyano, t ⁇ fluoromethyl group, C(O)NR4R5
  • R is carboxyhc acid
  • R i is preferably hydrogen, or R ] is preferably substituted in the 4-pos ⁇ t ⁇ on, more preferably substituted by t ⁇ fluoromethyl or chloro
  • R13 and R)4 are independently hydrogen or Ci-4 alkyl which may be straight or branched as defined herein, v is 0, or an integer having a value of 1 to 4.
  • Z is suitably cyano, OR j •* , C(O)NR ⁇ 5Ri ,
  • R15 and R 15 are independently hydrogen, optionally substituted C i -4 alkyl, optionally substituted aryl, optionally substituted aryl C ⁇ _4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocychc, optionally substituted heterocychcC ] _4alkyl, or 10 Rj5 and R ⁇ may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur
  • R 17 is C j -4 alkyl, NR 15R16, OR i j , optionally substituted aryl, optionally substituted aryl C 1 _4alkyl, optionally substituted heteroaryl. optionally i s substituted heteroarylC i_4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC 1 -4alkyl
  • R] g is suitably hydrogen, halogen, cyano, optionally substituted C i -4 alkyl, halo substituted -4 alkyl, C(O)NR
  • R13 and R 14 are independently hydrogen, optionally substituted C i -4 alkyl which may be straight or branched as defined herein, or one of R 13 and R 14 are an optionally substituted aryl, v is 0, or an 5 integer having a value of 1 to 4
  • Rj3 or R 14 are an optionally substituted alkyl
  • the alkyl moiety may be substituted one to three times independently by halogen; halosubstituted Ci-4 alkyl such as t ⁇ fluromethyl, hydroxy, hydroxy Ci-4alkyl, Ci-4 alkoxy; such as methoxy, or ethoxy, halosubstituted Cj -io alkoxy, S(O)tR4, aryl, NR4R5; 0 NHC(O)R4; C(O)NR4Rs; or C(O)OR 8 .
  • R20 suitably an optionally substituted C5_ cycloalkyl, optionally substituted C I _ IQ alkyl, optionally substituted C2- 10 alkenyl, or an optionally substituted C2-10 alkynyl moiety
  • R20 i an optionally substituted C5_ 8 cycloalkyl ring
  • the ring may be 5 substituted by (Y) n as defined below.
  • R20 1 an optionally substituted C [ . ⁇ Q alkyl, an optionally substituted - C2-10 alkenyl, or an optionally substituted C2-10 alkynyl
  • these moieties may be optionally substituted one or more times independently by halogen; nitro; cyano; halosubstituted Ci -io alkyl, such as t ⁇ fluoromethyl; Cj-io alkoxy; halosubstituted Ci-io alkoxy; S(O) ⁇ R4; hydroxy; hydroxy Ci -4alkyl; aryloxy; arylCi-4 alkyloxy; heteroaryloxy; heteroaryl Cj-4 alkyloxy; heterocychc; heterocychc C ⁇ _4alkyl; heterocychc-oxy; heterocychc C1.4
  • R20 ⁇ an optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl
  • these moieties may also, in addition to those moieties noted above, may also be optionally substituted with aryl, aryl C 1.4 alkyl, heteroaryl, and heteroarylalkyl.
  • Y is independently selected from hydrogen; halogen; nitro, cyano. halosubstituted C] .
  • s is preferably 1
  • Y forms an additional saturated or unsaturated ring, it is preferably 6 membered ring resulting in a naphthylene ring system
  • These rings may be substituted 1 to 3 times by other Y moieties as defined above.
  • Rj is a NRgR7, alkyl, aryl C1.4 alklyl, arylC 2-4 alkenyl, heteroaryl, hetroaryl-Ci-4 lkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychcC ⁇ _4 alkyl, or heterocychc C 2-4 alkenyl moiety, wherein the aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heterocychc, and heterocychcalkyl, and heterocychcalkenyl moieties noted above may all be optionally substituted as defined herein.
  • Y is preferably a halogen, C
  • Y is more preferably mono-substituted halogen, disubstituted halogen, mono-substituted alkoxy, disubstituted alkoxy, methylenedioxy, aryl, or alkyl, more preferably these groups are mono or di-substituted in the 2'- position or 2'-, 3 -position
  • Y may be substituted in any of the 5 ring positions when the ring is a cyclohexyl ring, Y is preferably mono-substituted in the 2'-pos ⁇ t ⁇ on or 3'- position, with the 4'- preferably being unsubstituted
  • R20 is a cycloalkyl moiety
  • both R ] and Y can both be hydrogen, it is prefered that at least one of the rings be substituted, preferably both rings are substituted
  • halogen such as fluorine, chlorine, bromine or iodine, hydroxy, hydroxy substituted C [ -ioalkyl.
  • R21 is suitably C i-4 alkyl, aryl, aryl C i -4alkyl, heteroaryl, heteroarylC 1. 4alkyl, heterocychc, or heterocychcC ⁇ _4alkyl.
  • Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fuma ⁇ c acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandehc acid
  • pharmaceutically acceptable salts of compounds of Formula (I) may also be lormed with a pharmaceutically acceptable cation, for instance, if a substituent group comp ⁇ ses a carboxy moiety
  • Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations .
  • cycloalkyl is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl,
  • alkenyl is used herein at all occurrences to mean straight or branched chain radical of 2- 10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1 -propenyl, 2-propenyl, 2-methyl- l - propenyl, 1-butenyl, 2-butenyl and the like
  • heteroaryl alkyl - a 5- 10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan. thiophene, quinohne, isoquinoline, quinazohnyl, pyndine, py ⁇ midine, oxazole, thiazole, thiadiazole, 5 t ⁇ azole, imidazole, or benzimidazole
  • heteroatoms selected from the group consisting of N, O, or S, such as, but not limited to, pyrrolidine, 0 piperidine, piperazine, morphohne, tetrahydropyran, or lmidazohdine
  • arylalkyl or “heteroarylalkyl” or “heterocychcalkyl” is used herein to mean C i-io alkyl, as defined above, attached to an aryl, heteroaryl or heterocychc moiety, as also defined herein, unless otherwise indicated
  • the compounds of the present invention may exist as stereoisomers, regioisomers, or diasterciomers These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. 10 All of these compounds are included within the scope of the present invention.
  • the compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below The synthesis I s provided for in these Schemes is applicable for the producing compounds of
  • R' represents the -(R 13R j 4) v -R20 linkage as defined in compounds of
  • the thiouronium salt (2_ ⁇ Scheme 1) can be synthesized by reacting sodium cyanamide with a commercially available isothiocyanate 1 (if the isothiocyanate is not commercially available it can be synthesized by reacting the desired amine with thiophosgene in the presence of a base like sodium bicarbonate).
  • the thiouronium salt (2) can then be condensed with the appropriate substituted aniline in the presence of a coupling reagent like EDC-HCl or acidified to form the cvanothiourea and then reacted.
  • Alternatively 4 can be synthesized by reacting the commercially available (Aldrich_Chem. Co.), diphenyl cyanocarboimidate (5, Scheme 2) with an amine to form an intermediate O-phenylisourea 6_which then reacts with the appropriately substituted aniline in the presence of trimethyl aluminum by the method of Atwal. (Atwal, K. S., Tetrahedron Lett, 35, 8085 ( 1994).).
  • Compounds wherein R' is alkyl may be prepared by heating with the appropriately substituted alkylamine, but without the presence of catalyst.
  • the title compound can be synthesized using a protected ortho- substituted aniline (8, Scheme 3, See synthesis as described in US provisional application USSN 60/020655 filed June 27, 1996, Attorney Docket No.: P50467P, WO96/25157 filed 22 August 1996, Widdowson et al (Attorney Docket No P50324- 1 ), and USSN 08/701.299 filed 21 August 1996 (Attorney Docket No . P50324-2) whose disclosures are incorporated herein by reference in their entireties
  • An ortho-substituted aniline (7, Scheme 3) is first protected Oe.
  • tert-butyl dimethyl silyl, allyl, benzyl, mom or other suitable protecting group by reacting the ortho- substituted aniline with the appropriate alkyl or silyl ha de in the presence of a suitable base (ic cesium carbonate, potassium carbonate or lmidazole) in an aprotic solvent
  • a suitable base ic cesium carbonate, potassium carbonate or lmidazole
  • the protected ortho-substituted aniline may also be synthesized from an ortho-substituted nitrobenzene (9 ) by reacting it with a protecting group under conditions well known m the art (see Greene, T Protecting Groups in Organic Synthesis.
  • This protected ortho-substituted aniline (8) can then be converted into an isothiocyanate using thiophosgene and then reacted with the anion ZNH" (formed from reaction of ZNH2 with a base such as NaH).
  • Z is as defined in compounds of
  • the thioimidate ( Q, Scheme 5) can be converted to the title compound 4 by reaction with the amine R'NH2- This reaction can be accelerated by the addition of metal salt with a high affinity for sulfur such as mercuric oxide or silver acetate or by oxidation of the sulfur with dimethyloxirane to form a better leaving group. Finally the phenol protection is removed by standard methods to form the title compound 4
  • Suitable bases for use herein include, secondary amine, such as py ⁇ dine, and amino substituted py ⁇ dine derivatives
  • suitable solvents for use herein when Z is cyano include various aprotic solvents, such as 0 acetonitnle, halogenated solvents, such as chloroform and methylene chloride; ethyl gylcol-dimethyl ether (monoGLYME), dioxane.
  • solvents herein will be the solubility of the cyano de ⁇ vatived compound.
  • Z is other than cyano
  • suitable solvents such as protic solvents, i.e. alcohols, may be used.
  • the reaction (when Z is cyano) temperature is from about - 10° to about 100°, preferably about 10° to about 50°, more preferably around room temperature, i.e. 20 to 30 °C. 0
  • the protected R" moiety may be suitably deprotected using art recognized techniques
  • the deprotection is by deallylation catalyzed by palladium (O) when the protecting group is an allyl derivative.
  • the carbodiimide JJ_ is prepared from the thiourea ( 12a, Scheme 7) by treatment with phosgene and a tertiary amine base or from the thiourea ( 12a) or urea ( 12b) by reaction with tnphenylphosphine, carbon tetrachlonde and triethylamine
  • the carbodiimide may also be prepared by reaction of the thiourea ( 12b) with an excess, such as 2 or more equivalents of methanesulfonyl chloride and a tertiary amine base, such as Hunig's base (diisopropylethyiamine), triethylamine, tn- lsopropylethylamine, N,N-d ⁇ methylbenzylam ⁇ ne, or N,N-d ⁇ methyhsopropylam ⁇ ne, preferably triethylamine.
  • reaction temperatures are from about -30°C to about 80°C, preferably - 10°C to about 50°C, more preferably from about 0°C to about room temperature. See Fell and Coppola (Fell, J. B , Coppola, J B , Syn Communications 25, 43, ( 1995)
  • the thiourea ( 12a. Scheme 8) may also be prepared by reaction of the protected ortho-substituted aniline and two equivalents of an appropriate base such as NaH, KH, calcium hydride, and reacting this anion with a commercially available isothiocyanate (Wj-NCS, wherein W - is as defined for compounds of Formula (I))
  • Wj-NCS isothiocyanate
  • the reaction make take place in any suitable aprotic solvent or halogenated solvent, preferably dimethyl formamide. Suitable reaction temperatures for this reaction are from about - 10° to about 50°.
  • the desired isothiocyanate is not commercially available, it may be prepared by reaction of a corresponding aniline with thiophosgene and a suitable base such as sodium bicarbonate.
  • compositions of Formula (I) may be 0 obtained in known manner, for example by treatment thereof with an appropriate amount of acid or base in the presence of a suitable solvent
  • the compounds of Formula (I), or a pharmaceutically acceptable salt thereof s can be used in the manufacture of a medicament tor the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and or macrophages, or other chemokmes which bind to the IL-8 a or b receptor, also referred to as the type I or type II 0 receptor
  • the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comp ⁇ ses administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof
  • the chemokmes are IL-8 GRO ⁇ , GRO ⁇ , GRO ⁇ . ENA-78 or NAP-2
  • the compounds ol Formula (I) are administered in an amount sufficient to inhibit cytokine function, in particular IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 or NAP-2 , such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state
  • Abnormal levels of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 or NAP-2 for instance in the context of the present invention constitute (1) levels of free IL-8 greater than or equal to 1 picogram per mL, (11) any cell associated IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 or NAP-2 above normal physiological levels, or (111) the presence of IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 or NAP-2 above basal levels in 5 cells or tissues in which IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 or NAP-2 respectively, is produced There are many disease states in
  • T-cell infiltration, or neovascular growth are associated with increased IL-8, GRO ⁇ , GRO ⁇ .
  • GRO ⁇ or NAP-2 production which is responsible for the chemotaxis of neutrophils into the inflammatory site or the directional growth of endothelial cells In contrast to other inflammatory cytokines (IL- 1 , TNF, and IL-6), IL-8, GRO ⁇ .
  • GRO ⁇ , GRO ⁇ or NAP-2 has the unique property of promoting neutrophil chemotaxis, enzyme release including but not limited to elastase release as well as superoxide production and activation
  • the ⁇ -chemokmes but particularly GRO ⁇ , GRO ⁇ , GRO ⁇ or NAP-2, working through the IL-8 type I or II receptor can promote the neovascula ⁇ zation of tumors by promoting the directional growth of endothelial cells Therefore, the inhibition of IL-8 induced chemotaxis or activation would lead to a direct reduction in the neutrophil infiltration
  • the present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I)
  • CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region Also included within this definition is ischemic stroke, particularly to the brain area
  • Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel
  • embolus a focal neurologic disorder that results from insufficient blood supply to a particular brain area
  • thrombi a progressive neurologic disorder that results from insufficient blood supply to a particular brain area
  • local atheromatous closure of the blood vessel The role of inflammatory cytokines in this are has been emerging and the present invention provides a mean for the potential treatment of these injuries Relatively little treatment, for an acute injury such as these has been available
  • TNF- ⁇ is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression
  • Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury See Liu et al., Stoke. Vol. 25 , No. 7, pp 1481-88 ( 1994) whose disclosure is incorporated herein by reference
  • the compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8. binding to the IL-8 alpha or beta receptors, from binding to these receptors, such as evidenced by a reduction in neutrophil chemotaxis and activation
  • the discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the in vitro receptor binding assays which are described herein
  • the compounds of Formula (I) have been shown, in some instances, to be dual inhibitors of both recombinant type I and type II IL-8 receptors.
  • the compounds are inhibitors of only one receptor, more preferably Type II
  • IL-8 mediated disease or disease state refers to any and all disease states in which IL-8, , GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 or NAP-2 plays a role, either by production oi IL-8, GRO ⁇ , GRO ⁇ . GRO ⁇ , ENA-78 or NAP-2 themselves, or by IL-8, GRO ⁇ . GRO ⁇ .
  • GRO ⁇ , ENA-78 or NAP-2 causing another monokine to be released such as but not limited to IL- 1 , IL-6 or TNF A disease state in which, for instance, IL- 1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8
  • chemokine mediated disease or disease state refers to any and all disease states in which a chemokine which binds to an IL-8 a or b receptor plays a role, such as but not limited to IL-8, GRO ⁇ , GRO ⁇ , GRO ⁇ , ENA-78 or NAP-2 This would include a disease state in which, IL-8 plays a role, either by production of IL-8 itself, or by IL-8 causing another monokine to be released, such as but not limited to IL-1 , IL-6 or TNF A disease state in which, tor instance.
  • IL-1 is a ma
  • cytokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response.
  • a cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them.
  • a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte.
  • Lymphokines are generally referred to as being produced by lymphocyte cells.
  • cytokines include, but are not limited to, Interleukin- 1 (IL- 1 ), Interleuk ⁇ n-6 (IL-6), Interleuk ⁇ n-8 (IL-8), Tumor Necrosis Factor-alpha (TNF- ⁇ ) and Tumor Necrosis Factor beta (TNF- ⁇ )
  • chemokine refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term "cytokine” above.
  • a chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and smooth muscle cells.
  • chemokmes include, but are not limited to, IL-8, GRO- ⁇ , GRO- ⁇ , GRO ⁇ , ENA-78, NAP-2, IP- 10, MlP- l a, MlP-b, PF4, and MCP 1 , 2, and 3
  • a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
  • This invention also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.
  • Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation.
  • the compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures.
  • the compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.
  • the pharmaceutical carrier employed may be. for example, either a solid or liquid.
  • solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, steanc acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge.
  • the amount of solid carrier will vary widely but preferably will be from about 25mg. to about lg
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
  • Compounds of Formula (I) may be administered topically, that is by non- systemic administration This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • the active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1 % to 1 % w/w of the formulation.
  • Lotions according to the present invention include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bacte ⁇ cide and may be prepared by methods similar to those for the preparation of drops
  • Lotions or liniments for application to the skin may 5 also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by l() mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base
  • the base may comprise hydrocarbons such as hard, solt or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage, an oil of natural origin such as almond, corn, arachis, castor or olive oil, wool fat oi
  • the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof
  • suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous 0 silicas, and other ingredients such as lanolin, may also be included
  • Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active 5 agent.
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 C for half an hour.
  • the solution may be sterilized by filtration and transferred to the container by an aseptic technique
  • bactericidal and fungicidal agents suitable for inclusion in the drops are 0 phenylmercunc nitrate or acetate (0.002%), benzalkonium chloride (0 01%) and chiorhexidine acetate (001 )
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol
  • Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, lntrarectal, intravaginal or 5 intraperitoneal administration.
  • the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
  • Appropriate dosage forms for such administration may be prepared by conventional techniques
  • Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration.
  • Appropriate dosage forms for such administration such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques
  • the daily oral dosage regimen will preferably be from about 001 to about 80 mg/kg of total body weight.
  • the daily parenteral dosage regimen about 0.001 to about 80 mg/kg of total body weight.
  • the daily topical dosage regimen will preferably be from 0 1 mg to 150 mg, administered one to four, preferably two or three times daily.
  • the daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day.
  • the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent ot the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course ot treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests
  • IL-8, and Gro- ⁇ chemokine inhibitiory effects of compounds of the present invention were determined by the following in vitro assay Receptor Binding Assays: [ 125 iL_g (human recombinant) is obtained from Amersham Corp.,
  • 0.5mM EDTA ethylene-diaminetetra- acetic acid
  • I mMPMSF ⁇ -toluenesulphonyl fluoride
  • 0.5 mg/L Leupeptin pH 7.5.
  • Membrane protein concentration is determined using Pierce Co. micro-assay kit using bovine serum albumin as a standard. All assays are performed in a 96-well micro plate format.
  • Each reaction mixture contains 1-51 IL-8 (0.25 nM) or 125j Gro- ⁇ and 0.5 ⁇ g/mL of IL-8R ⁇ or 1.0 ⁇ g/mL of IL-8R ⁇ membranes in 20 mM Bis- Trispropane and 0.4 mM Tris HC1 buffers, pH 8.0, containing 1.2 mM MgSO4, 0.1 mM EDTA, 25 mM NaCl and 0.03% CHAPS.
  • drug or compound of interest ss added which has been pre-dissoived in DMSO so as to reach a final concentration of between 0.0 InM and 100 uM.
  • the assay is initiated by addition of ⁇ 25I-IL-8.
  • the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1 % polyethylenimine/0.5% BSA and washed 3 times with 25 mM NaCl, 10 mM TrisHCl. 1 mM MgSOd, 0.5 mM EDTA, 0.03 % CHAPS. pH 7.4. The filter is then dried and counted on the Betaplate liquid scintillation counter.
  • the recombinant IL- 8 R ⁇ , or Type I, receptor is also referred to herein as the non-permissive receptor and the recombinant IL-8 R ⁇ , or Type II, receptor is referred to as the permissive receptor.
  • the in vitro inhibitory properties of these compounds are determined in the neutrophil chemotaxis assay as described in Current Protocols in Immunology, vol I, Suppl 1, Unit 6.12.3., whose disclosure is incorporated herein by reference in its entirety.
  • Neutrophils where isolated from human blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit 7.23.1 , whose disclosure is incorporated herein by reference in its entirety.
  • the chemoattractants IL-8, GRO- ⁇ , GRO- ⁇ , GRO- ⁇ and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0.1 and 100 nM. The two chambers are separated by a 5um polycarbonate filter.
  • the compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils.
  • Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit 7 23 1 PMNs 0 88 x IO 6 cells suspended in Ringer's Solution (NaCl 1 18. CI 4 56, NaHCO3 25. KH2PO4 1 03, Glucose 1 1 1 , HEPES 5 mM.
  • TNF- ⁇ in Traumatic Brain Injury Assay 0 The present assay provides for examination of the expression of tumor necrosis factor mRNA in specfic brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats
  • TBI experimentally induced lateral fluid- percussion traumatic brain injury
  • a marked increase of TNF- ⁇ mRNA expression is observed in LH ( 104 ⁇ i 7% of positive control, p ⁇ 0 05 compared with sham), LC ( 105 ⁇ 21 %, p ⁇ 005) and LA (69 ⁇ 8%, p ⁇ 0 01) m the traumatized hemisphere 1 hr following injury
  • An increased TNF- ⁇ mRNA expression is also observed in LH (46 ⁇ 8%, p ⁇ 005), LC (30 ⁇ 3%, p ⁇ 0 01
  • TNF- ⁇ mRNA is increased in RH (46 ⁇ 2%, p ⁇ 0 01), RC (4 ⁇ 3%) and RA (22 ⁇ 8%) at 1 hr and in RH (28 ⁇ 1 1 %), RC (7 ⁇ 5%) and RA (26 ⁇ 6%, p ⁇ 0 05) at 6 hr but not at 24 hr following injury
  • sham surgery without injury
  • naive animals no consistent changes in expression of TNF- ⁇ mRNA are observed in any ot the 6 brain areas in either hemisphere at any times
  • This assay characterizes the regional expression of interleukin- I B (IL- l ⁇ ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats
  • TBI lateral fluid-percussion traumatic brain injury
  • IL- l ⁇ interleukin- I B
  • LC left (injured) parietal cortex
  • RC contralateral right cortex
  • LA left parietal cortex
  • RA left hippocampus
  • RH right hippocampus
  • RNA Total RNA is isolated and Northern blot hybridization was performed and the quantity of brain tissue IL-l ⁇ mRNA is presented as percent relative radioactivity of IL-l ⁇ positive macrophage RNA which was loaded on same gel.
  • LH 24 5 ⁇ 0 9%, p ⁇ 005) and LA (21 5 ⁇ 3 1 %, p ⁇ 0 05) in the injured hemisphere, which remained elevated up to 6 hr.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to the use of compounds of formula (I) in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8). The variables of (I) are defined herein.

Description

IL-8 RECEPTOR ANTAGONISTS
FIELD OF THE INVENTION
This invention relates to novel guanidine substituted compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating IL-8, GROα, GROβ, GROγ and NAP-2 mediated diseases
BACKGROUND OF THE INVENTION
Many different names have been applied to Interleukιn-8 (IL-8), such as neutrophil attractant/activation protein- 1 (NAP-1 ), monocyte derived neutrophil chemotactic factor (MDNCF), neutrophil activating factor (NAF), and T-cell lymphocyte chemotactic factor Interleukιn-8 is a chemoattractant for neutrophils, basophils, and a subset of T-cells It is produced by a majority of nucleated cells including macrophages, fibroblasts, endothelial and epithelial cells exposed to TNF, IL-lα, IL-lβ or LPS, and by neutrophils themselves when exposed to LPS or chemotactic factors such as FMLP. M Baggio ni et al, J. Clin Invest 84. 1045 ( 1989), J Schroder et al, J. Immunol 139, 3474 ( 1987) and J Immunol 144. 2223 (1990) , Stπeter, et al, Science 243. 1467 ( 1989) and J Biol Chem. 264. 10621 (1989), Cassatella et al, J Immunol 148. 3216 (1992)
GROα, GROβ, GROγ, ENA-78 and NAP-2 also belong to the chemokine a family Like IL-8 these chemokmes have also been referred to by different names For instance Groα, GROβ, and GROγ have been referred to as MGSAα, β and γ respectively (Melanoma Growth Stimulating Activity), see Richmond et ai, J Cell Physiology 129, 375 (1986) and Chang et al, J Immunol 148, 451 (1992) All of the chemokmes of the a-family which possess the ELR motif directly preceding the CXC motif bind to the IL-8 B receptor. IL-8, GROα, GROβ, GROγ and NAP-2 stimulate a number of functions in vitro They have all been shown to have chemoattractant properties for neutrophils, while IL-8 and GROa have demonstrated T-lymphocytes, and basophiles chemotactic activity In addition IL-8 can induce histamine release from basophils from both normal and atopic individuals GRO-α and IL-8 can in addition, induce lysozomal enzyme release and respiratory burst from neutrophils IL-8 has also been shown to increase the surface expression of Mac- 1 (CD1 lb/CD 18) on neutrophils without de novo protein synthesis This may contribute to increased adhesion of the neutrophils to vascular endothelial cells Many known diseases are characterized by massive neutrophil infiltration As IL-8. Groα, GROβ, GROγ and NAP-2 promote the accumulation and activation of neutrophils, these chemokmes have been implicated in a wide range of acute and chronic inflammatory disorders including psoriasis and rheumatoid arthritis. Baggio ni et al. FEBS Lett 307. 97 ( 1992), Miller et al, Cπt Rev Immunol 12. 17 ( 1992), Oppenhei et al, Annu Rev
Immunol 9. 617 (1991). Seit? et al . J Clin Invest. 87. 463 (1991 ): Miller et al . Am Rev. Respir Pis 146. 427 (1992). Donnely et al , Lancet 341. 643 (1993) In addition the ELR chemokmes (those containing the amino acids ELR motif just prior to the CXC motif) have also been implicated in angiostasis Stπeter et al, Science 258, 1798 (1992)
In vitro, IL-8, GROα, GROβ, GROγ and NAP-2 induce neutrophil shape change, chemotaxis, granule release, and respiratory burst, by binding to and activating receptors of the seven-transmembrane, G-protein-hnked family, in particular by binding to IL-8 receptors, most notably the B-receptor Thomas et al , J Biol Chem 266. 14839 ( 1991 ). and Holmes et al . Science 253. 1278 ( 1991 ) The development of non-peptide small molecule antagonists for members of this receptor family has precedent For a review see R Freidinger in Progress in Drug Research. Vol 40, pp 33-98, Birkhauser Verlag, Basel 1993 Hence, the IL-8 receptor represents a promising target for the development of novel anti-inflammatory agents Two high affinity human IL-8 receptors (77% homology) have been characterized. IL-8Ra. which binds only IL-8 with high affinity, and IL-8Rb, which has high affinity for IL-8 as well as for GROα, GROβ, GROγ and NAP-2 See Holmes et al , supra; Murphy et al., Science 253. 1280 ( 1991), Lee et al , J Biol Chem 267. 16283 (1992), LaRosa et al , J Biol Chem 267. 25402 ( 1992), and Gavle et al . J Biol Chem 268. 7283 ( 1993)
There remains a need for treatment, in this field, tor compounds which are capable of binding to the IL-8 a or b receptor. Therefore, conditions associated with an increase in IL-8 production (which is responsible for chemotaxis of neutrophil and T-cells subsets into the inflammatory site) would benefit by compounds which are inhibitors of IL-8 receptor binding
SUMMARY OF THE INVENTION
This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In particular the chemokine is IL-8.
This invention also relates to a method of inhibiting the binding of IL-8 to its receptors in a mammal m need thereof which comprises administering to said mammal an effective amount of a compound of Formula (I).
Compounds of Formula (I) useful in the present invention are represented by the structure:
W— N — (CR.,R..)v R
H H 13 0 wherein Z is cyano, OR - j , R18, C(O)OR - j , C(O)Rj - , or S(O)2Rπ;
R is any functional moiety having an lomzable hydrogen and a pKa of 10 or less,
R | is independently selected from hydrogen; halogen; nitro; cyano: halosub.stituted Ci- io alkyl; C ι_ιo alkyl; C2-10 alkenyl; C i- io alkoxy; halosubstituted C i- io alkoxy; azide; (CR R8)q S(O)tR4; hydroxy; hydroxy C j-4alkyl; aryl; aryl C j-4 alkyl: aryloxy; aryl C| _4 alkyloxy; heteroaryl; heteroarylalkyl; heterocychc, heterocychc C i-4alkyl; heteroaryl C i-4 alkyloxy; aryl C2- 10 alkenyl; heteroaryl C2-10 alkenyl; heterocychc C2- 10 alkenyl; (CRgR8)qNR4R5; C2- 10 alkenyl C(O)NR4R5; (CR8R8)q C(O)NR R5; (CR8R8)q C(O)NR4R lθ; S(O)3H; S(O)3R8; (CR8R8)q C(O)Rι i ; C2- 10 alkenyl C(O)R] ] ; C2-10 alkenyl C(O)OR j j ; (CR8R8)q C(O)ORι ; (CR8R8)q OC(O) Ri j ;
(CR8R8)qNR4C(O)Rι i ; (CR8R8)q NHS(O)2Ri9; (CR8R8)q S(O)2NR4R5; or two R ] moieties together may form 0-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl and heterocychc containing moieties may be optionally substituted; q is 0, or an integer having a value of 1 to 10; t is 0, or an integer having a value of 1 or 2; m is an integer having a value of 1 to 3; s is an integer having a value of 1 to 3; v is 0, or an integer having a value of 1 to 4; R4 and R5 are independently hydrogen, optionally substituted C 1.4 alkyl, optionally substituted aryl, optionally substituted aryl Cj -4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C] -4alkyl, heterocychc, or heterocychc Ci-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from oxygen, nitrogen or sulfur. R6 and R7 are independently hydrogen or a C j -4 alkyl group, or R and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur, R is independently selected from hydrogen or C j-4 alkyl,
R l O is C i - io alkyl C(O)2R8,
R l 1 is hydrogen, C 1-4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi -4aikyl, optionally substituted heterocychc, or optionally substituted heterocychcC \ -4alkyl, R l2 is hydrogen, C j - io alkyl, optionally substituted aryl or optionally substituted arylalkyl, R 13 and R 14 are independently hydrogen or C ] -4 alkyl,
R l5 and Rj^ are independently hydrogen, optionally substituted C ) -4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylCi -4alkyl, optionally substituted heterocychc, optionally substituted heterocychcC j -4alkyl, 01 R 55 and R 16 may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur, R 17 is C 1 -4 alkyl, NR \ 5R 1 (., OR \ \ , optionally substituted aryl, optionally substituted aryl C ] -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocychc. or optionally substituted heterocychcC i -4alkyl, R l 8 is optionally substituted C i-4 alkyl, optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i -4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC i -4alkyl,
R l9 is C [ -4alkyI, aryl, arylalkyl, heteroaryl, heteroarylC] _4alkyl, heterocychc, or heterocychcC i-4alkyl, wherein the all of these moieties may be optionally substituted, is NR6R7, alkyl, arylC j_4 alkyl, arylC 2-4 alkenyl. heteroaryl, hetroaryl-Cj _4alkyl, heteroarylC2-4 alkenyl. heterocychc, heterocychcC 1.4 alkyl, wherein the alkyl. aryl, arylalkyl. heteroaryl, heteroaryl alkyl, heterocychc, and heterocychc alkyl rings may be optionally substituted, R20 is an optionally substituted C5_g cycloalkyl, optionally substituted C \ . \ Q alkyl, optionally substituted C2- 10 alkenyl, or optionally substituted C2-10
the E' containing ring is optionally selected from
ment of the ring; or a pharmaceutically acceptable salt thereof.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of Formula (I) may also be used in association with the veterinary treatment of mammals, other than humans, in need of inhibition of IL-8 or other chemokmes which bind to the IL-8 a and b receptors Chemokine mediated diseases for treatment, therapeutically or prophylactically, in animals include disease states such as those noted herein in the Methods of Treatment section
In compounds of Formula (I), W is suitably
The E' containing ring, denoted by its point of attachment through the asteπx
(*) may optionally be present If if it is not present the ring is a phenyl moiety which is substituted by the R \ terms as shown The E' ring may be substituted by
5 the Ri moiety in any ring, saturated or unsaturated, and is shown for purposes herein substituted only in the unsaturated πng(s)
R is suitably any functional moiety which provides an lonizable hydrogen having a pKa of 10 or less, preferably from about 3 to 9, more preferably from about 3 to 7 Such functional groups include, but are not limited to, hydroxy, carboxyhc
10 acid, thiol, SR2, OR2, NH-C(O)Ra, C(O)NR6'R7\ a substituted sulfonamides of the formula- NHS(O)2Rb, S(O)2NHRc> NHC(X2)NHRb, or a tetrazolyl; wherein X2 is oxygen or sulfur, preferably oxygen Preferably, the functional group is other than a sulfonic acid, either directly or as a substituent group on the aryl, heteroaryl, or heterocychc moiety ring, such as in SR2 or OR2 More preferably R is OH. SH, or i s NHS(O)2Rb
Suitably, R2 is a substituted aryl, heteroaryl, or heterocychc moiety which ring has the functional moiety providing the lonizable hydrogen having a pKa of 10 or less
Suitably, R6' and R7' are hydrogen, Ci-4 alkyl, aryl, arylC i -4alkyl, 0 arylC2-4alkenyl, heteroaryl, heteroarylC i-4alkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychc Cj-4alkyl, heterocychc C2-4alkenyl moiety , all of which may be optionally substituted one to three times independently by halogen; nitro, halosubstituted C1-4 alkyl, such as CF3, C 1.4 alkyl, such as methyl, C j-4 alkoxy, such as methoxy. NR9C(O)Ra, C(O)NR6R7, S(O)3H, or C(O)OC i-4 alkyl, S provided that only one of R6' and R7' are hydrogen, but not both
Suitably, R6 and R7 are independently hydrogen or a C i -4 alkyl group, or R and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur This heteroπng may be 0 optionally substituted as defined herein
Suitably Ra is an aryl, arylC i-4alkyl, heteroaryl, heteroarylC ] -4alkyl, heterocychc, or a heterocychc C | _4alkyl moiety, all of which may be optionally substituted, as defined herein below
Suitably, Rb is a NR6R7, alkyl, aryl, arylC |-4alkyl, arylC2-4alkenyl, 5 heteroaryl, heteroarylCi-4alkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychc C i-4alkyl, heterocychc C2-4alkenyl moiety, or camphor, all of which may be optionally substituted one to three times independently by halogen, nitro; halosubstituted Cj -4 alkyl, such as CF3; C i-4 alkyl, such as methyl, C 1-4 alkoxy, such as methoxy, NR9C(O)Ra, C(O)NR6R7; S(O)3H; or C(O)OCi -4 alkyl Rb is preferably an optionally substituted phenyl, benzyl, or styryl When Rb is a heteroaryl preferably it is an optionally substituted thiazole, optionally substituted thienyl, or optionally substituted quinohnyl ring
Suitably R9 is hydrogen or a C 1 -4 alkyl, preferably hydrogen Preferably, when the substituent group is NR9C(O)Ra, then Ra is preferably an alkyl group, such as methyl Suitably Rc is hydrogen, alkyl, aryl, arylCι_4alkyl, arylCj-4alkenyl, heteroaryl, heteroarylCi-4alkyl, heteroarylC i-4alkenyl, heterocychc, heterocychc C i-4alkyl, or heterocychc C ) -4alkenyl moiety, all of which may be optionally substituted one to three times independently by halogen, nitro, halosubstituted C j-4 alkyl, C1.4 alkyl, C i -4 alkoxy. NR9C(0)Ra, C(O)NR6R7, S(O)3H. or C(O)OCi-4 alkyl Preferably, Rc is an optionally substituted phenyl
When R is an OR2 or SR2 moiety it is recognized by one of skill in the art that the aryl ring must, therefore, contain the required lonizable hydrogen The aryl ring may also be additionally substituted, independently, by one to three groups, which groups may also contain an additional lonizable group, and which include but are not limited to, halogen, nitro, halosubstituted C 1 -4 alkyl, C 1.4 alkyl, C 1.4 alkoxy, hydroxy, SH, C(O)NR6R7, NH-C(O)Ra, NHS(O)2Rb- S(O)2NR6R7, C(O)OR8) or a tetrazolyl ring
In compounds of Formula (I), suitably R] is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted C j- io alkyl, such as CF3, C i-io alkyl, such as methyl, ethyl, isopropyl, or n-propyl; C2-10 alkenyl. C [_ ]0 alkoxy, such as methoxy, or ethoxy, halosubstituted C ]- |θ alkoxy. such as tπfluoromethoxy, azide; (CR8R )q S(O)tR4, wherein t is 0, 1 or 2; hydroxy, hydroxy Ci-4alkyl, such as methanol or ethanol, aryl, such as phenyl or naphthyl, aryl C ]-4 alkyl, such as benzyl; aryloxy, such as phenoxy; aryl C j -4 alkyloxy, such as benzyloxy; heteroaryl, heteroarylalkyl; heteroaryl C 1-4 alkyloxy; aryl C2-10 alkenyl; heteroaryl C2- 10 alkenyl; heterocychc C2- 10 alkenyl, (CRgRg)qNR4R5, C2- I0 alkenyl C(O)NR4R5, (CR8R8)q C(O)NR4R5; (CR8R8)q C(O)NR4Rlθ; S(O) H, S(O)3Rg, (CR8R8)q C(O)R 1 1 , C2-10 alkenyl C(O)R 1 13 C2- 10 alkenyl C(O)OR 1 1 , C(O)R 1 1 ; (CR8R8)q C(O)ORι2; (CR8R8)qOC(O)R ι 1 ; (CR8R8)q NR C(O)Rn , (CRgR8)q NHS(O)2Ri9, or (CR8R8)qS(O)2NR4R5; or two Rj moieties together may form O-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring; and s is an integer having a value of 1 to 3 The aryl , heteroaryl, and heterocychc containing moieites may be optionally substituted as defined herein below
Suitably, q is 0, or an integer having a value of 1 to 10
When Ri forms a dioxybπdge, s is preferably 1 When R[ forms an additional saturated or unsaturated ring, it is preferably 6 membered ring resulting in a naphthylene ring system These rings may be substituted independently, 1 to 3 times by the other Rj moieties as defined above
Suitably, R4 and R5 are independently hydrogen, optionally substituted Ci-4 alkyl, optionally substituted aryl, optionally substituted aryl C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C ]-4alkyl, heterocychc, heterocychcC 1-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from O/N/S.
Rg is suitably independently selected from hydrogen or C ( -4 alkyl Rio i suitably C\ .\() alkyl C(0)2Rg, such as CH2C(0)2H or
CH2C(0) CH3
Rl 1 is suitably hydrogen, Ci-4 alkyl, aryl, aryl C [ -4 alkyl. heteroaryl, heteroaryl C | _4alkyl, heterocychc, or heterocychc C i-4alkyl
R l2 is suitably hydrogen, C l- 10 alkyl, optionally substituted aryl or optionally substituted arylalkyl
Rj9 is C j-4alkyl, aryl, arylalkyl, heteroaryl, heteroarylCi-4alkyl, heterocychc, or heterocychcC i-4alkyl, wherein the all of these moieties may be optionally substituted.
Preferably Ri is halogen, cyano, nitro, CF3, C(O)NR4R5, alkenyl C(O)NR4R5, C(O) R4R 10. alkenyl C(0)OR ]2. heteroaryl, heteroarylalkyl , heteroaryl alkenyl, or S(O)NR4R5, and preferably R4 and R5 are both hydrogen or one is phenyl A preferred ring substitution for R i is in the 4-posιtιon of the phenyl ring.
When R is OH, SH or NSO2Rb than Rj is preferably mono-substituted in the 3-posιtιon, the 4- position or is di substituted in the 3,4- position The substituent group is suitably an electron withdrawing moiety Preferably when R is OH, SH or NSO2Rb. than Rl is nitro, halogen, cyano, tπfluoromethyl group, C(O)NR4R5
When R is carboxyhc acid, than R i is preferably hydrogen, or R ] is preferably substituted in the 4-posιtιon, more preferably substituted by tπfluoromethyl or chloro In compounds of Formula (I), suitably R13 and R)4 are independently hydrogen or Ci-4 alkyl which may be straight or branched as defined herein, v is 0, or an integer having a value of 1 to 4.
In compounds of Formula (I), Z is suitably cyano, OR j •* , C(O)NR { 5Ri ,
5 R 1 8, C(0)Rι j, C(O)OR, or S(O)2R ι7
Suitably R15 and R 15 are independently hydrogen, optionally substituted C i -4 alkyl, optionally substituted aryl, optionally substituted aryl C ι_4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocychc, optionally substituted heterocychcC ] _4alkyl, or 10 Rj5 and R \ may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur
Suitably, R 17 is C j -4 alkyl, NR 15R16, OR i j , optionally substituted aryl, optionally substituted aryl C 1 _4alkyl, optionally substituted heteroaryl. optionally i s substituted heteroarylC i_4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC 1 -4alkyl
In compounds of Formula (I), R] g is suitably hydrogen, halogen, cyano, optionally substituted C i -4 alkyl, halo substituted -4 alkyl, C(O)NR | 5R i , optionally substituted aryl, optionally substituted aryl C i -4alkyl, optionally 0 substituted heteroaryl, optionally substituted heteroarylC μ4alkyl. optionally substituted heterocychc, or optionally substituted heterocychcC 1 _4alkyl
In compounds of Formula (I), suitably R13 and R 14 are independently hydrogen, optionally substituted C i -4 alkyl which may be straight or branched as defined herein, or one of R 13 and R 14 are an optionally substituted aryl, v is 0, or an 5 integer having a value of 1 to 4
When Rj3 or R 14 are an optionally substituted alkyl, the alkyl moiety may be substituted one to three times independently by halogen; halosubstituted Ci-4 alkyl such as tπfluromethyl, hydroxy, hydroxy Ci-4alkyl, Ci-4 alkoxy; such as methoxy, or ethoxy, halosubstituted Cj -io alkoxy, S(O)tR4, aryl, NR4R5; 0 NHC(O)R4; C(O)NR4Rs; or C(O)OR8.
In compounds of Formula (I), R20 > suitably an optionally substituted C5_ cycloalkyl, optionally substituted C I _ IQ alkyl, optionally substituted C2- 10 alkenyl, or an optionally substituted C2-10 alkynyl moiety
When R20 i an optionally substituted C5_8 cycloalkyl ring, the ring may be 5 substituted by (Y)n as defined below. When R20 1 an optionally substituted C [ . \Q alkyl, an optionally substituted - C2-10 alkenyl, or an optionally substituted C2-10 alkynyl, these moieties may be optionally substituted one or more times independently by halogen; nitro; cyano; halosubstituted Ci -io alkyl, such as tπfluoromethyl; Cj-io alkoxy; halosubstituted Ci-io alkoxy; S(O){R4; hydroxy; hydroxy Ci -4alkyl; aryloxy; arylCi-4 alkyloxy; heteroaryloxy; heteroaryl Cj-4 alkyloxy; heterocychc; heterocychc Cι_4alkyl; heterocychc-oxy; heterocychc C1.4 alkyloxy; NR4R5; C(O)NR4R5; C(O)NR4R}0; S(O)3H; S(O)3R8; C(O)Rι 1 ; C(O)ORj2; OC(O)Rι 1 , or NR4C(O)Rj \ .
When R20 ι.s an optionally substituted C2-10 alkenyl, or an optionally substituted C2-10 alkynyl these moieties may also, in addition to those moieties noted above, may also be optionally substituted with aryl, aryl C 1.4 alkyl, heteroaryl, and heteroarylalkyl.
Suitably, Y is independently selected from hydrogen; halogen; nitro, cyano. halosubstituted C] .|o alkyl. C i - io alkyl: C2-K) alkenyl, Cj -K) alkoxy; halosubstituted Cj -io alkoxy: azide; (CR R8)q S(0)tR4; hydroxy, hydroxyC i-4alkyl; aryl; aryl C i -4 alkyl; aryloxy; arylC i -4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl C j -4 alkyloxy; heterocychc, heterocychc Ci -4alkyl; aryl C2-10 alkenyl; heteroaryl 2-10 alkenyl; heterocychc C2- 10 alkenyl; (CRgRg)q NR4R5; C2-IO alkenyl C(O)NR4R5; (CR8R8)q C(0)NR4R5; (CRgRg)q C(O)NR4Rlθ; S(O)3H; S(O)3R8, (CR8R8)q C(O)R] j ; C2-10 alkenyl C(O)R ) 1 ;
C2-10 alkenyl C(O)ORl 1 , (CR8R8)q C(O)ORl2; (CR8R8)q OC(O) Rj j ; (CR8Rg)q NR4C(O)Rl 1; (CR8Rg)q NHS(O)2Rd; or (CRgR8)q S(O)2NR4R5 or two Y moieties together may form 0-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring; wherein the aryl, heteroaryl, heterocychc containing moieties may be optionally substituted as defined herein.
When Y forms a dioxybπdge, s is preferably 1 When Y forms an additional saturated or unsaturated ring, it is preferably 6 membered ring resulting in a naphthylene ring system These rings may be substituted 1 to 3 times by other Y moieties as defined above. Suitably, Rj is a NRgR7, alkyl, aryl C1.4 alklyl, arylC 2-4 alkenyl, heteroaryl, hetroaryl-Ci-4 lkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychcC ι_4 alkyl, or heterocychc C 2-4 alkenyl moiety, wherein the aryl, arylalkyl, arylalkenyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heterocychc, and heterocychcalkyl, and heterocychcalkenyl moieties noted above may all be optionally substituted as defined herein. Y is preferably a halogen, C | -4 alkoxy, optionally substituted aryl, optionally substituted aryloxy or arylalkoxy, methylene dioxy, NR4R5, thio C ι_4alkyl, thioaryl, halosubstituted alkoxy, optionally substituted C i .4 alkyl, or hydroxy alkyl Y is more preferably mono-substituted halogen, disubstituted halogen, mono-substituted alkoxy, disubstituted alkoxy, methylenedioxy, aryl, or alkyl, more preferably these groups are mono or di-substituted in the 2'- position or 2'-, 3 -position
While Y may be substituted in any of the 5 ring positions when the ring is a cyclohexyl ring, Y is preferably mono-substituted in the 2'-posιtιon or 3'- position, with the 4'- preferably being unsubstituted In general, when R20 is a cycloalkyl moiety, while both R ] and Y can both be hydrogen, it is prefered that at least one of the rings be substituted, preferably both rings are substituted
As used herein, "optionally substituted" unless specifically defined shall mean such groups as halogen, such as fluorine, chlorine, bromine or iodine, hydroxy, hydroxy substituted C [ -ioalkyl. C ] _ ιo alkoxy, such as methoxy or ethoxy, S(O)m' C i -io alkyl, wherein m' is 0, 1 or 2, such as methyl thio, methyl sulfinyl or methyl sulfonyl, amino, mono & di-substituted amino, such as in the NR4R5 group, NHC(O)R4, C(O)NR4Rs, C(0)OH, S(0)2NR4Rs, NHS(O)2R21 , C | - 10 alkyl, such as methyl, ethyl, propyl, isopropyl, or t-butyl, halosubstituted C j - io alkyl, such CF3, an optionally substituted aryl, such as phenyl, or an optionally substituted arylalkyl, such as benzyl or phenethyl, optionally substituted heterocyhc, optionally substituted heterocyhcalkyl, optionally substituted heteroaryl, optionally substituted heteroaryl alkyl, wherein these aryl , hetroaryl, or heterocychc moieties may be substituted one to two times by halogen, hydroxy, hydroxy substituted alkyl, C j -io alkoxy, S(O)m'C i - i0 alkyl. amino, mono & di-substituted amino. such as in the NR4R5 group, C i - io alkyl, or halosubstituted C i - i o alkyl, such as CF3
R21 is suitably C i-4 alkyl, aryl, aryl C i -4alkyl, heteroaryl, heteroarylC 1. 4alkyl, heterocychc, or heterocychcC ι_4alkyl.
Suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of inorganic and organic acids, such as hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methane sulphonic acid, ethane sulphonic acid, acetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaπc acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid and mandehc acid In addition, pharmaceutically acceptable salts of compounds of Formula (I) may also be lormed with a pharmaceutically acceptable cation, for instance, if a substituent group compπses a carboxy moiety Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations .
The following terms, as used herein, refer to
• "halo" - all halogens, that is chloro. fluoro, bromo and lodo
• "C i- io lkyl" or "alkyl" - both straight and branched chain radicals of 1 to
10 carbon atoms, unless the chain length is otherwise limited, including, but not 10 limited to, methyl, ethyl, rc-propyl, wσ-propyl, /i-butyl, vec-butyl. ιso-buly\, tert- butyl, «-pentyl and the like
• The term "cycloalkyl" is used herein to mean cyclic radicals, preferably of 3 to 8 carbons, including but not limited to cyclopropyl, cyclopentyl, cyclohexyl,
i s • The term "alkenyl" is used herein at all occurrences to mean straight or branched chain radical of 2- 10 carbon atoms, unless the chain length is limited thereto, including, but not limited to ethenyl, 1 -propenyl, 2-propenyl, 2-methyl- l - propenyl, 1-butenyl, 2-butenyl and the like
• "aryl" - phenyl and naphthyl, 0 • "heteroaryl" (on its own or in any combination, such as "heteroaryloxy", or
"heteroaryl alkyl") - a 5- 10 membered aromatic ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O or S, such as, but not limited, to pyrrole, pyrazole, furan. thiophene, quinohne, isoquinoline, quinazohnyl, pyndine, pyπmidine, oxazole, thiazole, thiadiazole, 5 tπazole, imidazole, or benzimidazole
• "heterocychc" (on its own or in any combination, such as "heterocychcalkyl") - a saturated or partially unsaturated 4-10 membered ring system in which one or more rings contain one or more heteroatoms selected from the group consisting of N, O, or S, such as, but not limited to, pyrrolidine, 0 piperidine, piperazine, morphohne, tetrahydropyran, or lmidazohdine
• The term "arylalkyl" or "heteroarylalkyl" or "heterocychcalkyl" is used herein to mean C i-io alkyl, as defined above, attached to an aryl, heteroaryl or heterocychc moiety, as also defined herein, unless otherwise indicated
• "sultinyl" - the oxide S (O) of the corresponding sulfide, the term "thio ' 5 refers to the sulfide, and the term "sulfonyl' refers to the fully oxidized S(O)2 moiety • The term "wherein two R i moieties (or two Y moieties) may together form a 5 or 6 membered unsaturated ring" is used herein to mean the formation of a napthylene ring system or a phenyl moiety having attached a 6 membered partially unsaturated ring such as a Co cycloalkenyl, 1 e hexene, or a C5 cyloalkenyl moiety, s cyclopentene. It is recognized that in cases where the E ring is present it is unlikely that two R | monies will form another ring
It is recognized that the compounds of the present invention may exist as stereoisomers, regioisomers, or diasterciomers These compounds may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. 10 All of these compounds are included within the scope of the present invention.
Methods of Preparation
The compounds of Formula (I) may be obtained by applying synthetic procedures, some of which are illustrated in the Schemes below The synthesis I s provided for in these Schemes is applicable for the producing compounds of
Formula (I) having a variety of different R, R \ , and Aryl groups which are reacted, employing optional substituents which are suitably protected, to achieve compatibility with the reactions outlined herein. Subsequent deprotection, in those cases, then affords compounds of the nature generally disclosed Once the urea 0 nucleus has been established, further compounds of these formulas may be prepared by applying standard techniques for functional group interconversion, well known in the art While the schemes are shown with compounds only of Formula (I) this is merely for illustration purposes only.
5 The title compounds can be synthesized from the thiouronium salt (2,
Scheme 1 ) R' represents the -(R 13R j4)v-R20 linkage as defined in compounds of
Formula (I) For purposes of illustration herein the schemes represent the W term by a substituted phenyl.
Scheme
a)Na, EtOH, cyanamide b)EDC HCl
The thiouronium salt (2_ι Scheme 1) can be synthesized by reacting sodium cyanamide with a commercially available isothiocyanate 1 (if the isothiocyanate is not commercially available it can be synthesized by reacting the desired amine with thiophosgene in the presence of a base like sodium bicarbonate). The thiouronium salt (2) can then be condensed with the appropriate substituted aniline in the presence of a coupling reagent like EDC-HCl or acidified to form the cvanothiourea and then reacted.
Alternatively 4 can be synthesized by reacting the commercially available (Aldrich_Chem. Co.), diphenyl cyanocarboimidate (5, Scheme 2) with an amine to form an intermediate O-phenylisourea 6_which then reacts with the appropriately substituted aniline in the presence of trimethyl aluminum by the method of Atwal. (Atwal, K. S., Tetrahedron Lett, 35, 8085 ( 1994).). Compounds wherein R' is alkyl may be prepared by heating with the appropriately substituted alkylamine, but without the presence of catalyst. Scheme 2
a) acetonitπlc, heat b) Al e3
Alternatively the title compound can be synthesized using a protected ortho- substituted aniline (8, Scheme 3, See synthesis as described in US provisional application USSN 60/020655 filed June 27, 1996, Attorney Docket No.: P50467P, WO96/25157 filed 22 August 1996, Widdowson et al (Attorney Docket No P50324- 1 ), and USSN 08/701.299 filed 21 August 1996 (Attorney Docket No . P50324-2) whose disclosures are incorporated herein by reference in their entireties An ortho-substituted aniline (7, Scheme 3) is first protected Oe. tert-butyl dimethyl silyl, allyl, benzyl, mom or other suitable protecting group) by reacting the ortho- substituted aniline with the appropriate alkyl or silyl ha de in the presence of a suitable base (ic cesium carbonate, potassium carbonate or lmidazole) in an aprotic solvent The protected ortho-substituted aniline may also be synthesized from an ortho-substituted nitrobenzene (9 ) by reacting it with a protecting group under conditions well known m the art (see Greene, T Protecting Groups in Organic Synthesis. Wiley&Sons, New York, 1981) This protected ortho-substituted nitro compound is then reduced to the corresponding aniline using SnCl2 in EtOH or alternately H2 Pd or L1AIH4 in an aprotic solvent. Scheme 3
7 8
X = N, O, S ~
a) Alkyl or silyl hahde, base b) reducing agent
This protected ortho-substituted aniline (8) can then be converted into an isothiocyanate using thiophosgene and then reacted with the anion ZNH" (formed from reaction of ZNH2 with a base such as NaH). Z is as defined in compounds of
Formula (I).The resulting thioanion can then be alkylated with an alkylating agent like methyl iodide to form a thioimidate such as 10 (Scheme 4)
Scheme 4
m
a)ClCSCl, NaHCO3 b) ZNH' c)MeI
The thioimidate ( Q, Scheme 5) can be converted to the title compound 4 by reaction with the amine R'NH2- This reaction can be accelerated by the addition of metal salt with a high affinity for sulfur such as mercuric oxide or silver acetate or by oxidation of the sulfur with dimethyloxirane to form a better leaving group. Finally the phenol protection is removed by standard methods to form the title compound 4
Scheme 5
10
a) R'NH2 b) deprotect
io Alternately the title compound could be synthesized by reaction of a protected carbodnmide (JJ., Scheme 6) with the anion NH-Z (formed from reaction of NH2Z with a base such as NaH) or the neutral species NH2 (Z=CN) and a tertiary amine base, such as Hunig's base (dπsopropylethylamine). tπethylamine, tπ- isopropylethylam e, N,N-dιmethylbenzylamιne, or N,N-dιmethyhsopropylamιne, l s under conditions where the nucleophile is present in large excess and the reaction time is kept as short as possible by carefully monitoring the reaction for completion followed by deprotection Other suitable bases for use herein include, secondary amine, such as pyπdine, and amino substituted pyπdine derivatives Suitable solvents for use herein when Z is cyano include various aprotic solvents, such as 0 acetonitnle, halogenated solvents, such as chloroform and methylene chloride; ethyl gylcol-dimethyl ether (monoGLYME), dioxane. DMF and DMSO. or mixtures thereof, preferably acetonitnle. It is recognized by the skilled artisan that the limiting feature fo use of solvents herein will be the solubility of the cyano deπvatived compound. For compounds wherein Z is other than cyano, while 5 aprotic solvents are prefered, it is recognized by the skilled artisan that other suitable solvents, such as protic solvents, i.e. alcohols, may be used.
Preferably the reaction (when Z is cyano) temperature is from about - 10° to about 100°, preferably about 10° to about 50°, more preferably around room temperature, i.e. 20 to 30 °C. 0 The protected R" moiety may be suitably deprotected using art recognized techniques Preferably the deprotection is by deallylation catalyzed by palladium (O) when the protecting group is an allyl derivative. Scheme 6
a) ZNH - (ZNH2 + NaH) for Z=OR,COOEt,CHO, RNHSO ,ArNHSO2, b) ZNH2.HC1 for Z=OH c) ZNH2 and NR3 for Z= CN d) deprotect
The carbodiimide JJ_ is prepared from the thiourea ( 12a, Scheme 7) by treatment with phosgene and a tertiary amine base or from the thiourea ( 12a) or urea ( 12b) by reaction with tnphenylphosphine, carbon tetrachlonde and triethylamine The carbodiimide may also be prepared by reaction of the thiourea ( 12b) with an excess, such as 2 or more equivalents of methanesulfonyl chloride and a tertiary amine base, such as Hunig's base (diisopropylethyiamine), triethylamine, tn- lsopropylethylamine, N,N-dιmethylbenzylamιne, or N,N-dιmethyhsopropylamιne, preferably triethylamine. The reaction may use any halogenated solvent, such as methylene chloride, chloroform, or tetrachloroethylene, etc , suitable reaction temperatures are from about -30°C to about 80°C, preferably - 10°C to about 50°C, more preferably from about 0°C to about room temperature. See Fell and Coppola (Fell, J. B , Coppola, J B , Syn Communications 25, 43, ( 1995)
Scheme 7
R'
12a. X=S 12b. X=Q
a) phosgene, Et^N, b) Pl^P, CCI4, Et3N, c) MsCl, Et3N The thiourea or urea is synthesized as described in the US provisional application USSN 60/020655 filed June 27, 1996, Attorney Docket No : P50467P;
USSN 60/021973 filed June 27. 1996, Attorney Docket No.: P50469P; WO96/25157 filed 22 August 1996, Widdowson et al. (Attorney Docket No.: P50324- 1 ), and
USSN 08/701 ,299 filed 21 August 1996 (Attorney Docket No.: P50324-2) whose disclosures are incorporated herein by reference. The thiourea ( 12a. Scheme 8) may also be prepared by reaction of the protected ortho-substituted aniline and two equivalents of an appropriate base such as NaH, KH, calcium hydride, and reacting this anion with a commercially available isothiocyanate (Wj-NCS, wherein W - is as defined for compounds of Formula (I)) The reaction make take place in any suitable aprotic solvent or halogenated solvent, preferably dimethyl formamide. Suitable reaction temperatures for this reaction are from about - 10° to about 50°. If the desired isothiocyanate is not commercially available, it may be prepared by reaction of a corresponding aniline with thiophosgene and a suitable base such as sodium bicarbonate.
Scheme 8
S 12b
a) base b) R' NCS
Another aspect of the present invention are the novel compounds of Formula (II)
R20-N=C=N-W (II) wherein W, and R20-are as defined for formula (I), and W contains a protected or unprotected R group (R") as defined for compounds of Formula (I).
Another aspect of the present invention are the novel compounds of Formula
(III) R2()-NH-C(S)-NH-W (III) wherein W, and R20 are as defined for formula (I), and W contains a protected or unprotected R group (R") as defined for compounds of Formula (I)
Also, the protected (R") versions of compounds of Formula (I) are s contemplated as being within the scope of this invention
It is recognized that the guanidine functionality may hve a number of different tautomers, such as R20"N -C(=NZ) -NW. ZN =C(N R20) -NW, R20- -C(=NW) -NZ, all of which are within the scope of this invention
Pharmaceutically acceptable salts of compounds of Formula (I) may be 0 obtained in known manner, for example by treatment thereof with an appropriate amount of acid or base in the presence of a suitable solvent
METHOD OF TREATMENT
The compounds of Formula (I), or a pharmaceutically acceptable salt thereof s can be used in the manufacture of a medicament tor the prophylactic or therapeutic treatment of any disease state in a human, or other mammal, which is exacerbated or caused by excessive or unregulated IL-8 cytokine production by such mammal's cell, such as but not limited to monocytes and or macrophages, or other chemokmes which bind to the IL-8 a or b receptor, also referred to as the type I or type II 0 receptor
Accordingly, the present invention provides a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 a or b receptor and which method compπses administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof In 5 particular, the chemokmes are IL-8 GROα, GROβ, GROγ. ENA-78 or NAP-2
The compounds ol Formula (I) are administered in an amount sufficient to inhibit cytokine function, in particular IL-8, GROα, GROβ, GROγ, ENA-78 or NAP-2 , such that they are biologically regulated down to normal levels of physiological function, or in some case to subnormal levels, so as to ameliorate the disease state Abnormal levels of IL-8, GROα, GROβ, GROγ, ENA-78 or NAP-2 for instance in the context of the present invention, constitute (1) levels of free IL-8 greater than or equal to 1 picogram per mL, (11) any cell associated IL-8, GROα, GROβ, GROγ, ENA-78 or NAP-2 above normal physiological levels, or (111) the presence of IL-8, GROα, GROβ, GROγ, ENA-78 or NAP-2 above basal levels in 5 cells or tissues in which IL-8, GROα, GROβ, GROγ, ENA-78 or NAP-2 respectively, is produced There are many disease states in which excessive or unregulated IL-8 production is implicated in exacerbating and or causing the disease Chemokine mediated diseases include psoriasis, atopic dermatitis, arthritis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, inflammatory bowel disease. Crohn's disease, ulcerative colitis, stroke, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cardiac and renal reperfusion injury, glomerulonephπtis. thrombosis, graft vs host reaction, alzheimers disease, allograft rejections, malaria, restinosis, angiogenesis or undesired hematopoietic stem cells release These diseases are primarily characterized by massive neutrophil infiltration,
T-cell infiltration, or neovascular growth, and are associated with increased IL-8, GROα, GROβ. GROγ or NAP-2 production which is responsible for the chemotaxis of neutrophils into the inflammatory site or the directional growth of endothelial cells In contrast to other inflammatory cytokines (IL- 1 , TNF, and IL-6), IL-8, GROα. GROβ, GROγ or NAP-2 has the unique property of promoting neutrophil chemotaxis, enzyme release including but not limited to elastase release as well as superoxide production and activation The α-chemokmes but particularly GROα, GROβ, GROγ or NAP-2, working through the IL-8 type I or II receptor can promote the neovasculaπzation of tumors by promoting the directional growth of endothelial cells Therefore, the inhibition of IL-8 induced chemotaxis or activation would lead to a direct reduction in the neutrophil infiltration
Recent evidence also implicates the role of chemokmes in the treatment of HIV infections, Littleman et al , Nature 381 , pp661 ( 1996) and Koup et al , Nature 381, pp 667 ( 1996) The present invention also provides for a means of treating, in an acute setting, as well as preventing, in those individuals deemed susceptible to, CNS injuries by the chemokine receptor antagonist compounds of Formula (I)
CNS injuries as defined herein include both open or penetrating head trauma, such as by surgery, or a closed head trauma injury, such as by an injury to the head region Also included within this definition is ischemic stroke, particularly to the brain area
Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel The role of inflammatory cytokines in this are has been emerging and the present invention provides a mean for the potential treatment of these injuries Relatively little treatment, for an acute injury such as these has been available
TNF-α is a cytokine with proinflammatory actions, including endothelial leukocyte adhesion molecule expression Leukocytes infiltrate into ischemic brain lesions and hence compounds which inhibit or decrease levels of TNF would be useful for treatment of ischemic brain injury See Liu et al., Stoke. Vol. 25 , No. 7, pp 1481-88 ( 1994) whose disclosure is incorporated herein by reference
Models ot closed head injuries and treatment with mixed 5-LO/CO agents is discussed m Shohami et al . J of Vaisc & Clinical Physiology and Pharmacology, Vol 3, No. 2, pp. 99-107 ( 1992) whose disclosure is incorporated herein by reference Treatment which reduced edema formation was found to improve functional outcome in those animals treated
The compounds of Formula (I) are administered in an amount sufficient to inhibit IL-8. binding to the IL-8 alpha or beta receptors, from binding to these receptors, such as evidenced by a reduction in neutrophil chemotaxis and activation The discovery that the compounds of Formula (I) are inhibitors of IL-8 binding is based upon the effects of the compounds of Formulas (I) in the in vitro receptor binding assays which are described herein The compounds of Formula (I) have been shown, in some instances, to be dual inhibitors of both recombinant type I and type II IL-8 receptors. Preferably the compounds are inhibitors of only one receptor, more preferably Type II
As used herein, the term "IL-8 mediated disease or disease state" refers to any and all disease states in which IL-8, , GROα, GROβ, GROγ, ENA-78 or NAP-2 plays a role, either by production oi IL-8, GROα, GROβ. GROγ, ENA-78 or NAP-2 themselves, or by IL-8, GROα. GROβ. GROγ, ENA-78 or NAP-2 causing another monokine to be released, such as but not limited to IL- 1 , IL-6 or TNF A disease state in which, for instance, IL- 1 is a major component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8 As used herein, the term "chemokine mediated disease or disease state" refers to any and all disease states in which a chemokine which binds to an IL-8 a or b receptor plays a role, such as but not limited to IL-8, GROα, GROβ, GROγ, ENA-78 or NAP-2 This would include a disease state in which, IL-8 plays a role, either by production of IL-8 itself, or by IL-8 causing another monokine to be released, such as but not limited to IL-1 , IL-6 or TNF A disease state in which, tor instance. IL-1 is a ma|or component, and whose production or action, is exacerbated or secreted in response to IL-8, would therefore be considered a disease stated mediated by IL-8. As used herein, the term "cytokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response. A cytokine includes, but is not limited to, monokines and lymphokines, regardless of which cells produce them. For instance, a monokine is generally referred to as being produced and secreted by a mononuclear cell, such as a macrophage and/or monocyte. Many other cells however also produce monokines, such as natural killer cells, fibroblasts, basophils, neutrophils, endothelial cells, brain astrocytes, bone marrow stromal cells, epideral keratinocytes and B-lymphocytes. Lymphokines are generally referred to as being produced by lymphocyte cells. Examples of cytokines include, but are not limited to, Interleukin- 1 (IL- 1 ), Interleukιn-6 (IL-6), Interleukιn-8 (IL-8), Tumor Necrosis Factor-alpha (TNF-α) and Tumor Necrosis Factor beta (TNF-β) As used herein, the term "chemokine" refers to any secreted polypeptide that affects the functions of cells and is a molecule which modulates interactions between cells in the immune, inflammatory or hematopoietic response, similar to the term "cytokine" above. A chemokine is primarily secreted through cell transmembranes and causes chemotaxis and activation of specific white blood cells and leukocytes, neutrophils, monocytes, macrophages, T-cells, B-cells, endothelial cells and smooth muscle cells. Examples of chemokmes include, but are not limited to, IL-8, GRO- α, GRO-β, GROγ, ENA-78, NAP-2, IP- 10, MlP- l a, MlP-b, PF4, and MCP 1 , 2, and 3
In order to use a compound of Formula (I) or a pharmaceutically acceptable salt thereof in therapy, it will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. This invention, therefore, also relates to a pharmaceutical composition comprising an effective, non- toxic amount of a compound of Formula (I) and a pharmaceutically acceptable carrier or diluent.
Compounds of Formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions incorporating such may conveniently be administered by any of the routes conventionally used for drug administration, for instance, orally, topically, parenterally or by inhalation. The compounds of Formula (I) may be administered in conventional dosage forms prepared by combining a compound of Formula (I) with standard pharmaceutical carriers according to conventional procedures. The compounds of Formula (I) may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable character or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables The carrιer(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof The pharmaceutical carrier employed may be. for example, either a solid or liquid. Exemplary of solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, steanc acid and the like. Exemplary of liquid carriers are syrup, peanut oil, olive oil, water and the like. Similarly, the carrier or diluent may include time delay material well known to the art, such as glyceryl mono-stearate or glyceryl distearate alone or with a wax.
A wide variety of pharmaceutical forms can be employed Thus, if a solid carrier is used, the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will vary widely but preferably will be from about 25mg. to about lg When a liquid carrier is used, the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampule or nonaqueous liquid suspension.
Compounds of Formula (I) may be administered topically, that is by non- systemic administration This includes the application of a compound of Formula (I) externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose. The active ingredient may comprise, for topical administration, from 0.001% to 10% w/w, for instance from 1% to 2% by weight of the formulation. It may however comprise as much as 10% w/w but preferably will comprise less than 5% w/w, more preferably from 0.1 % to 1 % w/w of the formulation. Lotions according to the present invention include those suitable for application to the skin or eye. An eye lotion may comprise a sterile aqueous solution optionally containing a bacteπcide and may be prepared by methods similar to those for the preparation of drops Lotions or liniments for application to the skin may 5 also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil
Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by l() mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base The base may comprise hydrocarbons such as hard, solt or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage, an oil of natural origin such as almond, corn, arachis, castor or olive oil, wool fat oi
15 its derivatives or a fatty acid such as steπc or oleic acid together with an alcohol such as propylene glycol or a macrogel. The formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous 0 silicas, and other ingredients such as lanolin, may also be included
Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active 5 agent. The resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 C for half an hour. Alternatively, the solution may be sterilized by filtration and transferred to the container by an aseptic technique Examples of bactericidal and fungicidal agents suitable for inclusion in the drops are 0 phenylmercunc nitrate or acetate (0.002%), benzalkonium chloride (0 01%) and chiorhexidine acetate (001 ) Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol
Compounds of formula (I) may be administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, lntrarectal, intravaginal or 5 intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. Appropriate dosage forms for such administration may be prepared by conventional techniques Compounds of Formula (I) may also be administered by inhalation, that is by intranasal and oral inhalation administration. Appropriate dosage forms for such administration, such as an aerosol formulation or a metered dose inhaler, may be prepared by conventional techniques
For all methods of use disclosed herein for the compounds of Formula (I), the daily oral dosage regimen will preferably be from about 001 to about 80 mg/kg of total body weight. The daily parenteral dosage regimen about 0.001 to about 80 mg/kg of total body weight. The daily topical dosage regimen will preferably be from 0 1 mg to 150 mg, administered one to four, preferably two or three times daily. The daily inhalation dosage regimen will preferably be from about 0.01 mg/kg to about 1 mg/kg per day. It will also be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of Formula (I) or a pharmaceutically acceptable salt thereof will be determined by the nature and extent ot the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course ot treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt thereof given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests
The invention will now be described by reference to the following biological examples which are merely illustrative and arc not to be construed as a limitation of the scope of the present invention
BIOLOGICAL EXAMPLES
The IL-8, and Gro-α chemokine inhibitiory effects of compounds of the present invention were determined by the following in vitro assay Receptor Binding Assays: [ 125 iL_g (human recombinant) is obtained from Amersham Corp.,
Arlington Heights, IL, with specific activity 2000 Ci/mmol Gro-α is obtained from NEN- New England Nuclear. All other chemicals are of analytical grade High levels of recombinant human IL-8 type α and β receptors were individually expressed in Chinese hamster ovary cells as described previously (Holmes, et ai, Science, 1991, 253, 1278) The Chinese hamster ovary membranes were homogenized according to a previously described protocol (Haour, et al , J Biol Chem.. 249 pp 2195-2205 ( 1974)). Except that the homogenization buffer is changed to lOmM Tris-HCL. ImM MgS04. 0.5mM EDTA (ethylene-diaminetetra- acetic acid), I mMPMSF (α-toluenesulphonyl fluoride), 0.5 mg/L Leupeptin, pH 7.5. Membrane protein concentration is determined using Pierce Co. micro-assay kit using bovine serum albumin as a standard. All assays are performed in a 96-well micro plate format. Each reaction mixture contains 1-51 IL-8 (0.25 nM) or 125j Gro-α and 0.5 μg/mL of IL-8Rα or 1.0 μg/mL of IL-8Rβ membranes in 20 mM Bis- Trispropane and 0.4 mM Tris HC1 buffers, pH 8.0, containing 1.2 mM MgSO4, 0.1 mM EDTA, 25 mM NaCl and 0.03% CHAPS. In addition, drug or compound of interest ss added which has been pre-dissoived in DMSO so as to reach a final concentration of between 0.0 InM and 100 uM. The assay is initiated by addition of ■■25I-IL-8. After 1 hour at room temperature the plate is harvested using a Tomtec 96-well harvester onto a glass fiber filtermat blocked with 1 % polyethylenimine/0.5% BSA and washed 3 times with 25 mM NaCl, 10 mM TrisHCl. 1 mM MgSOd, 0.5 mM EDTA, 0.03 % CHAPS. pH 7.4. The filter is then dried and counted on the Betaplate liquid scintillation counter. The recombinant IL- 8 Rα, or Type I, receptor is also referred to herein as the non-permissive receptor and the recombinant IL-8 Rβ, or Type II, receptor is referred to as the permissive receptor.
Chemotaxis Assay :
The in vitro inhibitory properties of these compounds are determined in the neutrophil chemotaxis assay as described in Current Protocols in Immunology, vol I, Suppl 1, Unit 6.12.3., whose disclosure is incorporated herein by reference in its entirety. Neutrophils where isolated from human blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit 7.23.1 , whose disclosure is incorporated herein by reference in its entirety. The chemoattractants IL-8, GRO-α, GRO-β, GRO-γ and NAP-2 are placed in the bottom chamber of a 48 multiwell chamber (Neuro Probe, Cabin John, MD) at a concentration between 0.1 and 100 nM. The two chambers are separated by a 5um polycarbonate filter. When compounds of this invention are tested, they are mixed with the cells (0.001 - 1000 nM) just prior to the addition of the cells to the upper chamber. Incubation is allowed to proceed for between about 45 and 90 min at about 37°C in a humidified incubator with 5% CO2- At the end of the incubation period, the polycarbonate membrane is removed and the top side washed, the membrane then stained using the Diff Quick staining protocol (Baxter Products, McGaw Park, IL, USA). Cells which have chemotaxed to the chemokine are visually counted using a microscope. Generally, four fields are counted for each sample, these numbers are averaged to give the average number of cells which had migrated. Each sample is tested in triplicate and each compound repeated at least tour times To certain cells (positive control cells) no compound is added, these cells represent the maximum chemotactic response of the cells 5 In the case where a negative control (unstimulated) is desired, no chemokine is added to the bottom chamber. The difference between the positive control and the negative control represents the chemotactic activity of the cells
Elastase Release Assay
10 The compounds of this invention are tested for their ability to prevent Elastase release from human neutrophils. Neutrophils are isolated from human blood as described in Current Protocols in Immunology Vol I, Suppl 1 Unit 7 23 1 PMNs 0 88 x IO6 cells suspended in Ringer's Solution (NaCl 1 18. CI 4 56, NaHCO3 25. KH2PO4 1 03, Glucose 1 1 1 , HEPES 5 mM. pH 7 4) are placed in each well of a 96 well plate in i s a volume of 50 ul To this plate is added the test compound (0 001 - 1000 nM) in a volume of 50 ul, Cytochalasin B in a volume of 50 ul (20ug/ml) and Ringers buffer in a volume of 50 ul These cells are allowed to warm (37 °C, 5% CO2, 95% RH) for 5 min before IL-8, GROα, GROβ, GROγ or NAP-2 at a final concentration of 0.01 - 1000 nM was added The reaction is allowed to proceed for 45 min before the 96 well plate is 0 centrifuged (800 xg 5 min) and 100 ul of the supernatant removed This suppernatant is added to a second 96 well plate followed by an artificial elastase substrate (MeOSuc- Ala-Ala-Pro-Val-AMC, Nova Biochem, La Jolla, CA) to a final concentration ot 6 ug/ml dissolved in phosphate buffered saline. Immediately, the plate is placed in a fluorescent 96 well plate reader (Cytofluor 2350, Milhpore. Bedford, MA) and data 5 collected at 3 min intervals according to the method of Nakajima et al J Biol Chem 254 4027 ( 1979) The amount of Elastase released from the PMNs is calculated by measuring the rate of MeOSuc-Ala-Ala-Pro-Val-AMC degradation
TNF-α in Traumatic Brain Injury Assay 0 The present assay provides for examination of the expression of tumor necrosis factor mRNA in specfic brain regions which follow experimentally induced lateral fluid- percussion traumatic brain injury (TBI) in rats Adult Sprague-Dawley rats (n=42) were anesthetized with sodium pentobarbital (60 mg/kg, l p.) and subjected to lateral fluid- percussion brain injury of moderate severity (2.4 atm ) centered over the left 5 temporaparietal cortex (n= 18), or "sham" treatment (anesthesia and surgery without injury, n=18) Animals are sacrificed by decapitation at 1 , 6 and 24 hr. post injury, brains removed, and tissue samples ot left (injured) parietal cortex (LC), corresponding area in the contralateral right cortex (RC), cortex adjacent to injured parietal cortex (LA), corresponding adjacent area in the right cortex (RA), left hippocampus (LH) and right hippocampus (RH) are prepared Total RNA was isolated and Northern blot hybridization is performed and quantitated relative to an TNF-α positive control RNA (macrophage = 100%) A marked increase of TNF- α mRNA expression is observed in LH ( 104±i 7% of positive control, p < 0 05 compared with sham), LC ( 105±21 %, p< 005) and LA (69±8%, p < 0 01) m the traumatized hemisphere 1 hr following injury An increased TNF- α mRNA expression is also observed in LH (46±8%, p < 005), LC (30±3%, p < 0 01) and LA (32±3%, p < 0 01) at 6 hr which resolves by 24 hr. following injury In the contralateral hemisphere, expression of TNF- α mRNA is increased in RH (46±2%, p < 0 01), RC (4±3%) and RA (22±8%) at 1 hr and in RH (28±1 1 %), RC (7±5%) and RA (26±6%, p < 0 05) at 6 hr but not at 24 hr following injury In sham (surgery without injury) or naive animals, no consistent changes in expression of TNF- α mRNA are observed in any ot the 6 brain areas in either hemisphere at any times These results indicate that following parasagittal fluid-percussion brain injury, the temporal expression of TNF-α mRNA is altered in specific brain regions, including those of the non- traumatized hemisphere Since TNF- α is able to induce nerve growth factor (NGF) and stimulate the release of other cytokines from activated astrocytes, this post-traumatic alteration in gene expression of TNF-α plays an important role in both the acute and regenerative response to CNS trauma
CNS Iniurv model for IL-β mRNA
This assay characterizes the regional expression of interleukin- I B (IL- lβ) mRNA in specific brain regions following experimental lateral fluid-percussion traumatic brain injury (TBI) in rats Adult Sprague-Dawley rats (n=42) are anesthetized with sodium pentobarbital (60 mg/kg, 1 p ) and subjected to lateral fluid-percussion brain injury of moderate severity (2 4 atm ) centered over the left temporaparietal cortex (n=18), or "sham" treatment (anesthesia and surgery without injury) Animals are sacrificed at 1 , 6 and 24 hr post injury, brains removed, and tissue samples of left (injured) parietal cortex (LC), corresponding area in the contralateral right cortex (RC), cortex adjacent to injured parietal cortex (LA), corresponding adjacent area in the right cortex (RA), left hippocampus (LH) and right hippocampus (RH) are prepared. Total RNA is isolated and Northern blot hybridization was performed and the quantity of brain tissue IL-lβ mRNA is presented as percent relative radioactivity of IL-lβ positive macrophage RNA which was loaded on same gel. At 1 hr. following brain injury, a marked and significant increase in expression of IL- lβ mRNA is observed in LC (200±0.7% of positive control, n=6, p < 005 compared with sham animal). LH (24 5±0 9%, p < 005) and LA (21 5±3 1 %, p < 0 05) in the injured hemisphere, which remained elevated up to 6 hr. post injury in the LC (4 O±O 4%, n=6, p < 0 05) and LH (5 0±1.3%, p < 0.05) In sham or naive animals, no expression of IL- l β mRNA is observed in any of the respective brain areas These results indicate that following TBI. the temporal expression of IL-l β mRNA is regionally stimulated in specific brain regions These regional changes in cytokines, such as IL- l β play a role in the post-traumatic
All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth The above description fully discloses the invention including preferred embodiments thereof Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims Without further elaboration, it is believed that one skilled in the are can, using the preceding description, utilize the present invention to its fullest extent Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows

Claims

What is Claimed Is.
1 A method of treating a chemokine mediated disease state, wherein the chemokine binds to an IL-8 a or b receptor in a mammal, which comprises administering to said mammal an effective amount of a compound of the formula:
IM'
W—N N— (CR,,R, — R
H H 3 4 20 wherein Z is cyano. ORj j , C(O)NR15R16, R] 8, C(O)OR| j , C(O)Rj j , or S(O) Ri7;
R is any functional moiety having an lonizable hydrogen and a pKa of 10 or less,
R l is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted Cj - io alkyl; C μ io alkyl: C2- 10 alkenyl; C ' -io alkoxy; halosubstituted C | -io alkoxy; azide; (CR8Rg)q S(O)tR4; hydroxy; hydroxy Ci-4alkyl; aryl; aryl Cj-4 alkyl; aryloxy; aryl Ci-4 alkyloxy; heteroaryl; heteroarylalkyl; heterocychc, heterocychc C i-4alkyl; heteroaryl C ] -4 alkyloxy; aryl C2- 10 alkenyl; heteroaryl C2- 10 alkenyl; heterocychc C2-10 alkenyl; (CRgR )qNR4R5; C2- 10 alkenyl C(O)NR4R5, (CR8R8)q C(O)NR4R5J (CR8R8)q C(O)NR4R io; S(O)3H, S(O)3R8; (CR8R8)q C(O)R u ; C2- 10 alkenyl C(O)R u ; C2-1O alkenyl C(O)OR 1 1 ; (CR8R8)q C(O)OR 12; (CR8R8)q OC(O) R 1 1 ;
(CR8R8)qNR4C(O)Rι 1 ; (CR8R8)q NHS(O)2R ι9, (CR8R8)q S(O)2NR4R5; or two Rj moieties together may form 0-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl and heterocychc containing moieties may be optionally substituted; q is 0, or an integer having a value of 1 to 10; t is 0, or an integer having a value of 1 or 2, m is an integer having a value of 1 to 3; s is an integer having a value of 1 to 3; v is 0, or an integer having a value of 1 to 4; R4 and R5 are independently hydrogen, optionally substituted C 1-4 alkyl, optionally substituted aryl, optionally substituted aryl C |-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C i-4alkyl, heterocychc, or heterocychc C1-4 alkyl, or R4 and R5 together with the nitrogen to which they are attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from oxygen, nitrogen or sulfur, R6 and R7 are independently hydrogen or a C 1.4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur; R8 is independently selected from hydrogen or C 1.4 alkyl,
RlO i C i-10 alkyl C(O)2R8,
Rj 1 is hydrogen, C i-4 alkyl, optionally substituted aryl, optionally substituted aryl C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC ] -4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC 1 -4alkyl, R l 2 i hydrogen, C j - io alkyl, optionally substituted aryl or optionally substituted arylalkyl, R 13 and R ]4 are independently hydrogen or C [ -4 alkyl
R (5 and R j 6 are independently hydrogen, optionally substituted C i-4 alkyl, optionally substituted aryl, optionally substituted aryl C ] -4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i -4alkyl, optionally substituted heterocychc, optionally substituted heterocychcC ] -4alkyl, or R 15 and R j 6* may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from oxygen, nitrogen, or sulfur, R 17 is C 1-4 alkyl, NR 15R 16, OR i j , optionally substituted aryl, optionally substituted aryl C i -4alkyl. optionally substituted heteroaryl, optionally substituted heteroarylC j _4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC i -4alky I, R l is optionally substituted C j -4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC ι _4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC ι _4alkyl,
R l9 is C ] -4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC i-4alkyl, heterocychc, or heterocychcC i -4alkyl, wherein the all of these moieties may be optionally substituted, R20 is an optionally substituted C5.V cycloalkyl, optionally substituted C ι_ ιo alkyl, optionally substituted C2-10 alkenyl, or optionally substituted C2-10 alkynyl; the E' containing ring is optionally selected from
ment of the ring, or a pharmaceutically acceptable salt thereof
2 The method according to Claim 1 wherein the lonizable hydrogen has a pKa of 3 to 10
3 The method according to Claim 1 wherein R is hydroxy, carboxyhc acid, thiol, SR2, OR2, NH-C(O)Ra, C(O)NR6'R7\ NHS(O)2Rb, S(O)2NHRc, NHC(X2)NHRb, or tetrazolyl. wherein R2 is a substituted aryl, heteroaryl, or heterocychc moiety which ring has the functional moiety providing the lonizable hydrogen having a pKa of 10 or less,
R6' and R71 are hydrogen, -4 alkyl, aryl, arylC i-4alkyl, arylC2-4alkenyI, heteroaryl, heteroarylC ι_4alkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychc Ci-4alkyl, heterocychc C2-4alkenyl moiety , all of which may be optionally substituted one to three times independently by halogen, nitro, halosubstituted C [-4 alkyl; Cj-4 alkyl; Cι_4 alkoxy; NRoC(O)Ra, C(O)NRβR7, S(O)3H, or C(O)OC i-4 alkyl, provided that one of R6' and R7' are hydrogen, but not both,
R6 and R7 are independently hydrogen or a C 1.4 alkyl group, or R and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur;
Ra is an alkyl, aryl, aryl Ci-4alkyl, heteroaryl, heteroaryl Ci-4alkyl, heterocychc, or a heterocychc Ci-4alkyl moiety, all of which may be optionally substituted;
Rb is a NR6R7, alkyl, aryl, arylCι_4alkyl, aryiC2-4alkenyl, heteroaryl, heteroarylC i-4alkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychc Ci-4alkyl, heterocychc C2-4alkenyl moiety, camphor, all of which may be optionally substituted one to three times independently by halogen; nitro; halosubstituted Cj-4 alkyl; C1-4 alkyl, C\-4 alkoxy; NR9C(O)Ra, C(O)NR6R7; S(O)3H; orC(O)OC]-4 alkyl,
R9 is hydrogen or a C ] .4 alkyl,
Rc is alkyl, aryl, arylC[-4alkyl, arylC2-4alkenyl, heteroaryl, heteroarylC i-4alkyl, heteroarylC2-4alkenyl. heterocychc, heterocychc Ci-4alkyl, or a heterocychc C2-4alkenyl moiety, all of which may be optionally substituted one to three times independently by halogen, nitro, halosubstituted Ci-4 alkyl, C)-4 alkyl, C1-4 alkoxy, NR9C(O)Ra, C(O)NR6R7, S(O)3H, or C(O)OCi-4 alkyl; and
X2 is oxygen or sulfur.
4. The method according to Claim 3 wherein the R2 is optionally substituted one to three times by halogen, nitro, halosubstituted C 1-10 alkyl, Ci-io alkyl, Cj-io alkoxy, OH. SH, C(O)NRβR7. NH-C(O)Ra, NHS(0)2Rb, S(O)NR6R7, C(O)OR ι or a tetrazolyl ring.
5 The method according to Claim 3 wherein R is OH, NHS(0)2Rb or
C(O)OH.
6. The method according to Claim 1 wherein Ri is halogen, cyano, nitro. CF3, C(O)NR4R5, alkenyl C(O) R4R5, C(O) R4R10, alkenyl C(O)ORi2, heteroaryl, heteroarylalkyl , heteroaryl alkenyl, or S(O)NR4R5.
7. The method according to Claim 1 wherein R IS a C3-5 cycloalkyl optionally substituted by (Y)n;
Y is independently selected from hydrogen; halogen; nitro; cyano; halosub.stituted Cj-io alkyl; Ci-io alkyl, C2-io alkenyl, Cj-io alkoxy; halosubstituted Cj-io alkoxy; azide; (CR R8)q S(O)tR4; hydroxy; hydroxyC)-4alkyl; aryl, aryl Ci-4 alkyl, aryloxy; arylCi-4 alkyloxy; heteroaryl; heteroarylalkyl; heteroaryl C| -4 alkyloxy; heterocychc, heterocychc C i-4alkyl, aryl C2- 10 alkenyl; heteroaryl C2-10 alkenyl, heterocychc C2-10 alkenyl; (CR8Rg)q NR4R5; C2-10 alkenyl C(O)NR4R5; (CR8R8)q C(O)NR4R5, (CR8R8)q C(O)NR4Rjo; S(O)3H, S(O) R8, (CR8R8)q C(O)R] 1 , C - 10 alkenyl C(O)R ι 1 ; C2-10 alkenyl
C(O)OR 1 1 ; C(O)R 1 1 ; (CR8R8)q C(O)OR 12, (CR8R8)q OC(O) Rn ; (CR8R8)q NR4C(O)Rj 1 ; (CRgRg)q NHS(O)2Rd; (CR8R8)q S(O)2NR4R5; or two Y moieties together may form O-(CH )sO- or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl and heterocychc moieties may be optionally substituted; n is an integer having a value of 1 to 3; and
Rj is NRgR7, alkyl, arylC| _4 alkyl, arylC 9.4 alkenyl, heteroaryl, hetroaryl-C ι _4alkyl, heteroaryiC2_4 alkenyl, heterocychc, heterocychcC 1.4 alkyl, wherein the alkyl, aryl, heteroaryl, and heterocychc containing rings may be optionally substituted
8. The method according to Claim I wherein R is OH, SH, or NHS(O)2Rb and
Rl is substituted in the 3-posιtιon, the 4- position or di substituted in the 3,4- position by an electron withdrawing moiety
9 The method according to any of Claims 1 to 8 wherein the mammal is afflicted with a chemokine mediated disease selected from psoriasis, or atopic dermatitis, asthma, chronic obstructive pulmonary disease, adult respiratory distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephntis, thrombosis, neurotrauma, alzheimers disease, graft vs. host reaction, or allograft rejections
10 A compound of the formula:
wherein Z is cyano, ORi C(O)NRι5R16, R18, C(O)ORπ , C(O)Rι j, or S(O)2Rι7,
R is any functional moiety having an lonizable hydrogen and a pKa of 10 or less,
Rl is independently selected from hydrogen; halogen; nitro; cyano; halosubstituted C i-io alkyl; Ci-io alkyl, C2-10 alkenyl; C j- io alkoxy, halosubstituted C i-io alkoxy, azide; (CR R8)q S(O)tR4; hydroxy; hydroxy Ci-4alkyl, aryl; aryl Cj-4 alkyl; aryloxy; aryl Ci-4 alkyloxy; heteroaryl; heteroarylalkyl, heterocychc, heterocychc C i-4alkyl; heteroaryl Cj-4 alkyloxy; aryl C2-10 alkenyl, heteroaryl C2- 10 alkenyl; heterocychc C2-10 alkenyl; (CR R )qNR4R5; 2-10 alkenyl C(O)NR R5; (CR8R8)q C(O)NR4R5; (CR8R8)q C(O)NR Rl0; S(O)3H; S(O)3R8; (CR8R8)q C(O)Rι 1 , C2-10 alkenyl C(O)Rι 1 , C2-10 alkenyl
C(O)ORj 1 , (CR8R8)q C(O)ORι2; (CR8R8)q OC(O) Rj 1 , (CR8R8)qNR4C(O)Rι 1; (CR8R8)q NHS(O)2R19, (CR8R8)q S(O)2NR4R5, or two Rj moieties together may form O-(CH2)sO- or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl and heterocychc containing moieties may be optionally substituted. q is 0, or an integer having a value of 1 to 10; t is 0, or an integer having a value of 1 or 2, m is an integer having a value of 1 to 3, s is an integer having a value of 1 to 3, v is 0, or an integer having a value of 1 to 4,
R4 and R5 are independently hydrogen, optionally substituted Ci -4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroaryl C i-4alkyl, heterocychc, or heterocychc Ci-4 alkyl, or R4 and R5 together with the nitrogen to which they arc attached form a 5 to 7 member ring which may optionally comprise an additional heteroatom selected from oxygen, nitrogen or sulfur;
R6 and R7 are independently hydrogen or a Cj-4 alkyl group; or R and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom selected from oxygen, nitrogen or sulfur;
R is independently selected from hydrogen or C j-4 alkyl,
RlO is Cl- lO alkyl C(O)2R8;
R l 1 is hydrogen, Cj-4 alkyl, optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC 1 -4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC 1 -4alkyl; R 12 is hydrogen, Cj -io alkyl. optionally substituted aryl or optionally substituted arylalkyl,
Rl3 and R 14 are independently hydrogen or C j-4 alkyl;
Rj5 and Rig are independently hydrogen, optionally substituted C]-4 alkyl, 5 optionally substituted aryl, optionally substituted aryl C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i-4alkyl, optionally substituted heterocychc, optionally substituted heterocychcC ι_4alkyl, or R 15 and Rj6 may together with the nitrogen to which they are attached form a 5 to 7 member ring optionally containing an additional heteroatom selected from
10 oxygen, nitrogen, or sulfur,
R 17 is C 1-4 alkyl, NR15R1 , ORj j , optionally substituted aryl, optionally substituted aryl Ci-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC j _4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC i-4alkyl, i s j g is optionally substituted C i-4 alkyl, optionally substituted aryl, optionally substituted aryl C i-4alkyl, optionally substituted heteroaryl, optionally substituted heteroarylC i -4alkyl, optionally substituted heterocychc, or optionally substituted heterocychcC i-4alkyl; R]9 is C ] -4alkyl, aryl, arylalkyl, heteroaryl, heteroarylC | -4alkyl, heterocychc, or 0 heterocychcC 1 -4alkyl, wherein the all of these moieties may be optionally substituted; R2o 1S an optionally substituted C5_ cycloalkyl, optionally substituted Cι_jø alkyl, optionally substituted C2-io alkenyl, or optionally substituted 2-io alkynyl, 5
the E' containing ring is optionally selected from ment of the ring; or a pharmaceutically acceptable salt thereof.
5 1 1. The compound according to Claim 10 wherein the lonizable hydrogen has a pKa of 3 to 10.
12. The compound according to Claim 10 wherein R is hydroxy, carboxyhc acid, thiol, SR2, OR2, NH-C(O)Ra, C(O)NR6'R7', NHS(0)2Rb, S(O)2NHRc, o NHC(X2)NHRb, or tetrazolyl; wherein R2 is a substituted aryl, heteroaryl, or heterocychc moiety which ring has the functional moiety providing the lonizable hydrogen having a pKa of 10 or less;
R6' and R7' are hydrogen, C] _4 alkyl, aryl, arylCi-4alkyl, arylC2-4alkenyl, 5 heteroaryl, heteroarylC i-4alkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychc C i-4alkyl, heterocychc C2-4alkenyl moiety , all of which may be optionally substituted one to three times independently by halogen, nitro; halosubstituted C ]-4 alkyl, -4 alkyl; C 1-4 alkoxy, NR9C(O)Ra; C(0)NR6R7, S(O)3H, or C(O)OC j-4 alkyl, provided that one of R6" and R7' are hydrogen, but not both; 0 Rf and R7 are independently hydrogen or a C 1.4 alkyl group, or R6 and R7 together with the nitrogen to which they are attached form a 5 to 7 member ring which ring may optionally contain an additional heteroatom which heteroatom is selected from oxygen, nitrogen or sulfur;
Ra is an alkyl, aryl, aryl Ci-4alkyl, heteroaryl, heteroaryl C i-4alkyl, 5 heterocychc, or a heterocychc C 1 -4alkyl moiety, all of which may be optionally substituted;
Rb is a NR6R7, alkyl, aryl, arylC i-4alkyl, arylC2-4alkenyl. heteroaryl, heteroarylC i -4alkyl, heteroarylC2-4 alkenyl, heterocychc, heterocychc Ci-4alkyl, heterocychc C2-4alkenyl moiety, camphor, all of which may be optionally substituted one to three times independently by halogen, nitro; halosubstituted Ci .4 alkyl, C 1-4 alkyl, Cj-4 alkoxy; NR9C(O)Ra, C(O)NR6R7, S(O)3H, or C(O)OCι_4 alkyl; R9 is hydrogen or a Ci-4 alkyl,
Rc is alkyl, aryl, arylCi-4alkyl, arylC2-4alkenyl, heteroaryl, heteroarylC i-4alkyl, heteroarylC2-4alkenyl, heterocychc, heterocychc C[-4alkyl, or a heterocychc C2-4alkenyl moiety, all of which may be optionally substituted one to three times independently by halogen, nitro, halosubstituted Ci-4 alkyl, C]-4 alkyl, C1-4 alkoxy, NR9C(O)Ra, C(O)NR6R7, S(O)3H, or C(O)OCι_4 alkyl; and
X is oxygen or sulfur.
13 The compound according to Claim 12 wherein the R2 is optionally substituted one to three times by halogen, nitro, halosubstituted Ci-io alkyl, Ci-io alkyl, Cj-io alkoxy, OH, SH, C(O)NR6R7, NH-C(O)Ra, NHS(O)Rb, S(O)NRόR7, C(O)OR8ι or a tetrazolyl ring
14 The compound according to Claim 12 wherein R is OH, NHS(O)2Rb or C(O)OH; or R is OH, SH, or NHS(O)2Rb and Rj is substituted in the 3-posιtιon, the 4- position or di substituted in the 3,4- position by an electron withdrawing moiety
15 The compound according to Claim 10 wherein Rj is halogen, cyano, nitro, CF3, C(O)NR4R5, alkenyl C(O)NR4R5, C(O) R4R10, alkenyl C(O)ORi2, heteroaryl, heteroarylalkyl , heteroaryl alkenyl, or S(O)NR4R5
16. The compound according to Claim wherein R Q is a C5_ cycloalkyl optionally substituted by (Y)n;
Y is independently selected from hydrogen; halogen, nitro; cyano; halosubstituted Ci-io alkyl; Ci-io alkyl; C2-10 alkenyl; Cj-io alkoxy; halosubstituted Cj-io alkoxy, azide; (CR R )q S(O)tR4; hydroxy; hydroxyCi-4alkyl, aryl; aryl Ci-4 alkyl; aryloxy; arylCj-4 alkyloxy; heteroaryl; heteroarylalkyl, heteroaryl Cj-4 alkyloxy; heterocychc, heterocychc Ci-4alkyl, aryl C2-IO alkenyl; heteroaryl C2-10 alkenyl; heterocychc C2-10 alkenyl; (CR R8)q NR4R5; C2-IO alkenyl C(O)NR4R5; (CR8R8)q C(O)NR4R5; (CR8R8)q C(O)NR4RlO, S(O)3H; S(O)3R8; (CR8R8)q C(O)Ri 1; C2-10 alkenyl C(O)Rj 1, C2- 10 alkenyl
C(O)ORι 1, C(O)Rι i; (CR8R8)q C(O)ORι ; (CR8R8)q OC(O) Rn, (CR8R8)q NR4C(O)Rl l , (CR8R8)q NHS(O)2Rd, (CR8R8)q S(O)2NR4R5; or two Y moieties together may form O-(CH2) O- or a 5 to 6 membered saturated or unsaturated ring, and wherein the aryl, heteroaryl and heterocychc moieties may be optionally substituted; n is an integer having a value of 1 to 3; and
Rj is NRgR7, alkyl, arylC i-4 alkyl, arylC 2-4 alkenyl, heteroaryl, hetroaryl-C i _4aJkyl, heteroarylC _4 alkenyl, heterocychc, heterocychcC \ .4 alkyl, wherein the alkyl, aryl, heteroaryl, and heterocychc containing rings may be optionally substituted.
17. The compound according to Claim 10 wherein R o is an optionally substituted alkyl.
18 A pharmaceutical composition comprising a compound according to any of Claims 10 to 17, and a pharmaceutically acceptable carrier or diluent.
EP97939515A 1996-08-15 1997-08-15 Il-8 receptor antagonists Withdrawn EP0920253A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2399196P 1996-08-15 1996-08-15
US23991P 1996-08-15
PCT/US1997/014825 WO1998006262A1 (en) 1996-08-15 1997-08-15 Il-8 receptor antagonists

Publications (2)

Publication Number Publication Date
EP0920253A1 true EP0920253A1 (en) 1999-06-09
EP0920253A4 EP0920253A4 (en) 2001-10-17

Family

ID=21818277

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97939515A Withdrawn EP0920253A4 (en) 1996-08-15 1997-08-15 Il-8 receptor antagonists

Country Status (3)

Country Link
EP (1) EP0920253A4 (en)
JP (1) JP2001527519A (en)
WO (1) WO1998006262A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049400A1 (en) 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
CO5170514A1 (en) 1999-05-28 2002-06-27 Smithkline Beecham Corp ANTAGONISTS OF IL-8 RECEIVERS RECEIVERS OF IL-8
MY143477A (en) 2002-10-29 2011-05-31 Smithkline Beecham Corp Il-8 receptor antagonists
AU2005245399A1 (en) 2004-05-12 2005-12-01 Schering Corporation CXCR1 and CXCR2 chemokine antagonists
CL2007001142A1 (en) 2006-04-21 2008-01-25 Smithkline Beecham Corp Sulfone-derived compounds, il-8 receptor antagonists; preparation procedure; intermediary compounds; pharmaceutical composition; pharmaceutical combination; and use in the treatment of asthma, chronic obstructive pulmonary disease, dermatitis, psoriasis, Alzheimer's, atherosclerosis, osteoporosis.
WO2007124423A2 (en) 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0790240A1 (en) * 1996-02-15 1997-08-20 Tanabe Seiyaku Co., Ltd. Phenol-derivatives having pharmaceutical activity and process for preparing the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
US5290814A (en) * 1988-11-21 1994-03-01 Burroughs Wellcome Co. Anti-atherosclerotic diaryl compounds
US5441984A (en) * 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0790240A1 (en) * 1996-02-15 1997-08-20 Tanabe Seiyaku Co., Ltd. Phenol-derivatives having pharmaceutical activity and process for preparing the same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9806262A1 *

Also Published As

Publication number Publication date
WO1998006262A1 (en) 1998-02-19
EP0920253A4 (en) 2001-10-17
JP2001527519A (en) 2001-12-25

Similar Documents

Publication Publication Date Title
US6133319A (en) IL-8 receptor antagonists
US6271261B1 (en) IL-8 receptor antagonists
US6218539B1 (en) IL-8 receptor antagonists
US6204294B1 (en) IL-8 receptor antagonists
US6214881B1 (en) IL-8 receptor antagonists
WO1998006701A1 (en) Il-8 receptor antagonists
EP0907362A1 (en) Il-8 receptor antagonists
EP1005341B1 (en) Il-8 receptor antagonists
US6335352B1 (en) IL-8 receptor antagonists
US6248785B1 (en) IL-8 receptor antagonists
WO1998006398A1 (en) Il-8 receptor antagonists
US6177448B1 (en) IL-8 receptor antagonists
WO1998006262A1 (en) Il-8 receptor antagonists
WO1997049287A1 (en) Il-8 receptor antagonists
WO1998005328A1 (en) Il-8 receptor antagonists
WO2000076457A2 (en) Il-8 receptor antagonists
EP1185270A1 (en) Il-8 receptor antagonists
WO2000073282A1 (en) Il-8 receptor antagonists
WO2000076508A1 (en) Il-8 receptor antagonists
CA2377397A1 (en) Il-8 receptor antagonists
WO2000069435A1 (en) Il-8 receptor antagonists
WO2000076515A1 (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20010905

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07C 279/18 A, 7C 07C 279/28 B, 7C 07C 335/16 B, 7A 61K 31/355 B

17Q First examination report despatched

Effective date: 20020510

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020921